2002

AIDS Healthcare Foundation Awards 2002 'Heart of Stone' to British Pharmaceutical Giant GlaxoSmithKline: PRNewswire - December 31, 2002; LOS ANGELES, Dec. 31 /PRNewswire/ -- The US largest AIDS organization today awarded its 2002 Heart of Stone to British pharmaceutical giant GlaxoSmithKline for putting profit above human decency while 8,500 die every day of AIDS. AHF -- which provides medical care to uninsured AIDS patients from California to
Healthy Love or Destructive Obsession? Author of New Book Honored as a 2002 'Visionary': PRNewswire - December 28, 2002; CHICAGO, Dec. 28 /PRNewswire/ -- John D. Moore, a 32-year old therapist and professor of health sciences at American Public University announced today that Liberation Publications has identified him as a 2002 Visionary for his work in the social services field as it relates to HIV/AIDS. Moore is the author of a newly r
HIV/AIDS Specialist Regulation Approved by State of California: Landmark Bill Mandating HMO Access to HIV/AIDS Specialists to Take Effect Mid-January: PRNewswire - December 24, 2002; -- AB 2168 (Gallegos, D, Los Angeles, 2000) Requires Standing Referrals, State, Community & Medical Groups Worked Together to Craft Definition of Specialist LOS ANGELES, Dec. 24 /PRNewswire/ -- Groundbreaking legislation ordering California HMOs to provide standing referrals to AIDS specialists for patients infecte
Showtime Networks Presents WHAT'S GOING ON? : New Documentary Family Series From RCN Entertainment, in Association with The United Nations, to Focus on Issues Through a Child's Eyes: PRNewswire - December 23, 2002; -- Celebrity-hosted 10-Part Series of Specials to Begin Airing On SHOWTIME January 19, 2003 -- Danny Glover to Host Premiere Episode on HIV/AIDS Epidemic: Angelina Jolie, Jeff Bridges, Laurence Fishburne & Michael Douglas Serve As Episode Hosts -- Nicole Silver and Orly Wiseman to Executive Produce Series NEW YORK,
Roche's COBAS Ampliscreen System Tests Receive FDA Approval -- FDA Approves the COBAS AmpliScreen(TM) HCV Test, Version 2.0 and the COBAS AmpliScreen(TM) HIV-1 Test, Version 1.5: PRNewswire - December 23, 2002; INDIANAPOLIS, Dec. 23 /PRNewswire/ -- Following recent news of the U.S. Food and Drug Administration s ( FDA ) clearance of Roche Diagnostics COBAS AmpliScreen System for the blood banking industry, Roche is now pleased to announce FDA approval of the first two tests which are designed for use with this System -- the C
AIDS Healthcare Foundation Urges Stepped Up Involvement by US in Global AIDS Fight: Nation's Largest AIDS Organization Expresses Optimism About Likely Senate Majority Leader: PRNewswire - December 21, 2002; AIDS Healthcare Foundation Praises Physician/Senator s Medical Relief Work in Africa, Recognizes Frist s Leadership Sponsoring First US Global AIDS Funding Legislation LOS ANGELES, Dec. 21 /PRNewswire/ -- AIDS Healthcare Foundation, (AHF) the nation s largest AIDS organization which operates free AIDS clinics in the
Bristol-Myers Squibb Submits New Drug Application for Investigational Protease Inhibitior Atazanavir for Treatment of HIV Infection: PRNewswire - December 20, 2002; PRINCETON, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for atazanavir, an investigational protease inhibitor under development for the treatment of HIV/AIDS in combination
Vertex Pharmaceuticals Announces Submission of NDA/MAA Filings in U.S. And Europe for GW433908 for Treatment of HIV Infection: PRNewswire - December 20, 2002; CAMBRIDGE, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for marketing approval of GW433908 (also known as 908 or VX-175), an investigation
Additional Artists Answer Nelson Mandela's Call to Perform at Historic Human Rights Concert: Dave Stewart, Yusuf Islam, Bono, Queen, Macy Gray, Nelly Furtado, Coldplay, Shaggy, Eve, Ludacris and More Scheduled: PRNewswire - December 19, 2002; Nelson Mandela to Host Extraordinary Event: People s Concert to Take Place Simultaneously at South Africa s Green Point Stadium in Conjunction With Concert at Robben Island NEW YORK, Dec. 19 /PRNewswire/ -- Some of the world s most celebrated recording artists have come together to answer Nelson Mandela s SOS to eradic
Mental Health, HIV Patients Oppose Plan Being Considered by Governor Hodges To Cut Access to Medicaid Drugs: Patient - Physician Relationship Threatened by State Action: PRNewswire - December 19, 2002; COLUMBIA, S.C., Dec. 19 /PRNewswire/ -- It s Christmas time at the State Capital in Columbia, but several South Carolina patient groups are not in a holiday mood. A new state Medicaid drug plan -- being considered by outgoing Governor Hodges -- has South Carolina patient advocates very concerned. The prescription drug
Nation's Largest AIDS Organization Files for Preliminary Injunction Against Glaxo in AZT Patent Piracy Lawsuit: AHF's Anti-Trust Complaint Seeks to Overturn Glaxo Patent on AZT, Combivir & Trizivir AHF Cites Fraud During Patent Process as Reason to Invalidate GSK's Patents: PRNewswire - December 19, 2002; LOS ANGELES, Dec. 19 /PRNewswire/ -- The largest AIDS organization in the United States today announced that it has filed a motion for a Preliminary Injunction against GlaxoSmithKline (GSK) and related companies in its federal anti-trust complaint against the British-owned pharmaceutical giant. AIDS Healthcare Foundat
Groundbreaking Celebrity Event Will Help Fight Mother-to-Child HIV Transmission in India: - Richard Gere and Parmeshwar Godrej Bring Indian Celebrities Together to Host Fundraising and Awareness Building Event Benefiting Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - December 19, 2002; MUMBAI, India , Dec. 19 /PRNewswire/ -- In the first-ever event of its kind, leading Indian celebrities will gather in Mumbai, India on December 20 to raise awareness of India s HIV/AIDS epidemic, and to lend their support to efforts to reduce mother-to-child transmission of the virus. The event, A Time for Heroes Ind
The Immune Response Corporation Granted Patent in South Africa for Novel Formulation of REMUNE(R): Vaccine Formulation Using REMUNE(R) and Immunostimulatory Sequence Aimed at Preventive Applications: PRNewswire - December 19, 2002; CARLSBAD, Calif., Dec. 19 /PRNewswire-FirstCall/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today it has been granted Republic of South Africa Patent Number 2001/8559 entitled HIV Immunogenic Compositions and Methods for its latest vaccine development utilizing a novel formulation of REMUNE(R) in conce
Update on the Manufacture of Investigational HIV Drug FUZEON: First commercial scale production successfully completed: PRNewswire - December 18, 2002; NUTLEY, N.J., and DURHAM, N.C., Dec. 18 /PRNewswire-FirstCall/ -- As part of the stated commitment to keep interested parties informed on the development of their investigational HIV drug, Roche and Trimeris now have enough data from the first three months of experience of the commercial manufacturing process of FUZEON
Primagen's Mitox Tests for Mitochondrial Toxicity Highlighted In Presentations at the HIV-1 DART Conference: PRNewswire - December 18, 2002; AMSTERDAM, Netherlands , Dec. 18 /PRNewswire/ -- Primagen today presented new pre-clinical data on its proprietary Mitox tests at the HIV-1 DART conference in Florida, where frontiers in drug development for antiretroviral therapies are discussed among the worlds best drug developers and scientists. Primagen s Mito
Pharmacor Receives U.S. Patent for anti-HIV Integrase Inhibitor: PRNewswire - December 18, 2002; MONTREAL, Dec. 18 /PRNewswire/ - Pharmacor Inc. has been issued U.S. patent application no. 09/963,329 relating to its antiretroviral program. The small-molecule compounds described in the patent, entitled Aromatic derivatives with HIV integrase inhibitory properties, are novel anti-HIV lead molecules that target a nov
Showtime Networks Greenlights WHAT'S GOING ON?; New Documentary Family Series from RCN Entertainment, in Association with The United Nations, To Focus on Issues Through a Child's Eyes - Celebrity-Hosted 10-Part Series of Specials to Begin Airing On SHOWTIME in January 2003: PRNewswire - December 17, 2002; - Danny Glover to Host Premiere Episode on HIV/AIDS Epidemic - Angelina Jolie, Jeff Bridges, Laurence Fishburne & Michael Douglas Serve As Episode Hosts Nicole Silver and Orly Wiseman to Executive Produce Series NEW YORK, Dec. 17 /PRNewswire/ -- Showtime Networks has reached an agreement with RCN Entertainment to p
Hemispherx Presents New Data from Phase IIB Clinical Trial of RNA-based Ampligen(R) for Structured Treatment Interruption in HIV at DART Conference - Ampligen(R) Study Indicates Prolonged Time Off AIDS Drugs Without Viral Rebound: PRNewswire - December 17, 2002; PHILADELPHIA, Dec. 17 /PRNewswire-FirstCall/ -- Hemispherx Biopharma Inc. (Amex: HEB) today presented new data from a Phase IIB clinical trial of its experimental compound, RNA-based Ampligen(R), on Structured Treatment Interruption (STI) in HIV. Gary Blick, M.D. and Hemispherx s Clinical Director, David Strayer, M.D.,
Congresswoman Hilda Solis to Cut Ribbon as AIDS Healthcare Foundation, Bienestar Human Services Join Forces in Grand Opening of New El Monte HIV/AIDS Healthcare Center: PRNewswire - December 17, 2002; -- Partnership Between Nation s Largest AIDS Organization, Leading Southern California Latino AIDS Social Service Provider Offers Region s HIV/AIDS Patients Improved Access to Quality Care, Services in Greater El Monte EL MONTE, Calif., Dec. 17 /PRNewswire/ -- In an effort to better reach some under-served Los Angeles
Hemispherx Files New US Patent Application on Immune-Based Alternative Treatment to HIV/AIDS: Designed to Protect 'Sanctuary' Regions of the Body Where Virus Hides and Mutates into Drug Resistant Strains.: PRNewswire - December 16, 2002; PHILADELPHIA, Dec. 16 /PRNewswire/ -- Hemispherx Biopharma Inc. (Amex: HEB) has filed a US patent application (US Provisional No. 60/339,390) to develop a new immune-based treatment for HIV/AIDS. All of the approximately 18 existing approved therapies are antiretrovirals, and thus far uniformly directed only at the AID
VaxGen Receives Fast Track Designation from FDA for AIDSVAX B/B and AIDSVAX B/E: Conference Call Scheduled for 11 a.m. Eastern Time, Tuesday, December 17th: PRNewswire - December 16, 2002; BRISBANE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration ( FDA ) has designated HIV/AIDS vaccine candidates, AIDSVAX B/B and AIDSVAX B/E (rgp120), Fast Track Products for the prevention of HIV infection. The Fast Track designation will
Press Briefing On Smallpox Vaccination: PRNewswire - December 14, 2002; WASHINGTON, Dec. 14 /PRNewswire/ -- The following is a transcript of remarks by President Bush: GOVERNOR RIDGE: Good afternoon. The President has just outlined the plan to strengthen the security of America by improving significantly our capability to protect Americans in the event of a small pox attack. As he describe
Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U Magazine Article: International AIDS Publication Profiles Recently Initiated Israeli Clinical Trials: PRNewswire - December 12, 2002; YONKERS, N.Y., Dec. 12 /PRNewswire-FirstCall/ -- Advanced Viral Research Corporation (OTC Bulletin Board: ADVR) today announced that the potential for Company s Product R as treatment for AIDS was the subject of a recent article in A&U Magazine. This global publication is devoted to collecting, archiving, publishin
Joint Statement By the United States and the Republic of Kenya, And Ethiopia: PRNewswire - December 11, 2002; WASHINGTON, Dec. 11 /PRNewswire/ -- At the invitation of President George W. Bush, President Daniel T. Arap Moi of Kenya and Prime Minister Meles Zenawi of Ethiopia met at the White House on Thursday, December 5, 2002. The leaders reaffirmed their strong commitment in the global war on terrorism.
'AmeriCares Action for Africa' Program Calls on Worldwide Support Through Online Donations: PRNewswire - December 11, 2002; NEW CANAAN, Conn., Dec. 11 /PRNewswire/ -- AmeriCares, the international disaster relief agency, today announced the launch of a humanitarian aid and disaster relief effort to deliver medicines and nutritional supplements to hospitals and clinics in southern Africa and Ethiopia . The first in a six- month series of Ame
Results of New PROCRIT(R) Study in Critically Ill Patients Finds Reduction in Red Blood Cell Transfusions: Study Published in The Journal of the American Medical Association: PRNewswire - December 10, 2002; BRIDGEWATER, N.J., Dec. 10 /PRNewswire/ -- Results of a new study published today in The Journal of the American Medical Association found that critically ill patients who received once weekly PROCRIT(R) (Epoetin alfa) were ten percent less likely to receive red blood cell transfusions (RBCs) than patients in the place
Results of New PROCRIT(R) Study in Critically Ill Patients Finds Reduction in Red Blood Cell Transfusions: Study Published in The Journal of the American Medical Association: PRNewswire - December 10, 2002; BRIDGEWATER, N.J., Dec. 10 /PRNewswire/ -- Results of a new study published today in The Journal of the American Medical Association found that critically ill patients who received once weekly PROCRIT(R) (Epoetin alfa) were ten percent less likely to receive red blood cell transfusions (RBCs) than patients in the place
Transgene Signs Vaccine Manufacturing Agreement With International AIDS Vaccine Initiative: PRNewswire - December 10, 2002; STRASBOURG, France , Dec. 10 /PRNewswire-FirstCall/ -- Transgene announced today that it has entered into a collaborative agreement with the International AIDS Vaccine Initiative (IAVI) to manufacture pre-clinical lots of IAVI s constructs for a novel form of vaccine. These constructs, developed at the National Institu
Global Fund Launches Program to Fight AIDS Epidemic in Haiti: Haiti Becomes First Country Outside of Africa to Sign Grant Agreement With Global Fund: PRNewswire - December 9, 2002; WASHINGTON, Dec. 9 /PRNewswire/ -- The Government of Haiti signed this week an agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria, launching a program that will open a pipeline for grants totaling $67 million to the country over the next five years. It is the first such agreement for the Global Fund
Mymetics' Potent In Vitro AIDS Therapy Research Results to Be Presented at 10th Conference on Retroviruses and Opportunistic Infections: PRNewswire - December 9, 2002; ANNAPOLIS, Md., Dec. 9 /PRNewswire-FirstCall/ -- Mymetics Corporation today announced that the Company will present research findings on a new approach to treating HIV and other retroviral diseases at the 10th Conference on Retroviruses and Opportunistic Infections. Mymetics is testing a novel class of anti-retroviral
Mandela SOS Answered By Oprah Winfrey, Archbishop Desmond Tutu And Naomi Campbell: Nelson Mandela Sends Out an SOS on the AIDS Pandemic Across the World Calling for Awareness and Funds to Fight the HIV/AIDS Crisis: PRNewswire - December 6, 2002; Historic Mandela SOS Concert to Take Place on Robben s Island in South Africa on February 2, 2003 CAPE TOWN, South Africa, Dec. 6 /PRNewswire/ -- Nelson Mandela s SOS has been answered. At a launch event today at the National Botanical Gardens in Cape Town, Nelson Mandela, supported by Archbishop Desmond Tutu, Oprah Wi
Reused Medical Devices Pose Health and Safety Risk to Patients Survey Shows Majority of Doctors and Nurses Oppose Practice, Most Consumers Unaware of Practice: PRNewswire - December 5, 2002; MCLEAN, Va., Dec. 5 /PRNewswire/ -- The Center for Patient Advocacy today released a survey of surgeons, operating room nurses and consumers which reveals that health care professionals have grave concerns about the reuse of single use medical devices and their impact on patient health and safety. These devices, such a
Sundance Channel Joins Viacom in Company-Wide AIDS Initiative: Programming Includes Sundance Film Festival Award-Winner 'Silverlake Life: The View from Here': PRNewswire - December 5, 2002; NEW YORK, Dec. 5 /PRNewswire/ -- Sundance Channel joins Viacom in a company-wide initiative to raise awareness about the ongoing global AIDS crisis. As part of its efforts, Sundance Channel will present acclaimed documentary films about living with AIDS on January 13th and 14th. Monte Bramer s Paul Monette: The Brink o
Roche Receives FDA Clearance for the COBAS AmpliScreen System: Significantly Strengthens Roche's Position in the Blood Screening Business: PRNewswire - December 5, 2002; INDIANAPOLIS, Dec. 5 /PRNewswire-FirstCall/ -- Roche Diagnostics (Roche), based in Indianapolis, Ind., is pleased to announce that the U.S. Food and Drug Administration ( FDA ) has granted 510(k) clearance of the company s COBAS AmpliScreen System. The COBAS AmpliScreen System is intended for use in laboratories testin
AZT Scientists Joins GSK Patent Challenge: AIDS Drug's Recognized Co-Inventor, Dr. Hiroaki Mitsuya, Joins AIDS Healthcare Foundation President Michael Weinstein to Denounce Glaxo Patent Piracy: Former NIH Scientist Discovered AZT's Use Against HIV/AIDS: PRNewswire - December 5, 2002; -- Dr. Jerome P. Horwitz, Researcher Who First Discovered AZT in the 1960 s As A Possible Cancer-Fighting Drug Offers Letter Supporting AIDS Group s Effort to Invalidate Patent on AZT, Other HIV Drugs LONDON, Dec. 5 /PRNewswire/ -- The researcher who first demonstrated that the drug AZT (Retrovir(R) or zidovudine) supp
Mymetics Corporation Presents Data on Novel Anti-Retroviral Agents At Scientific Conference: PRNewswire - December 4, 2002; ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) today presented preclinical data at the International Feline Retrovirus Research Symposium demonstrating potent antiviral activity of five candidate compounds against FIV, the feline equivalent of HIV. The Mymetics peptides
FDA Approves Pegasys(R) (peginterferon alfa-2a) in Combination with Copegus(TM) (ribavirin) for the Treatment of Hepatitis C: New Treatment Offers Dosing Regimen Based on Hepatitis C Virus Strain: PRNewswire - December 3, 2002; NUTLEY, N.J., Dec. 3 /PRNewswire/ -- Roche announced today that the U.S. Food and Drug Administration ( FDA ) has approved combination therapy with Pegasys(R) (peginterferon alfa-2a), a pegylated interferon, and Copegus(TM) (ribavirin) for the treatment of adults with chronic
Trinity Companies, Inc. and Freedom from Hunger to Co-Develop Workplace-Based HIV/AIDS Education for Global Industries: PRNewswire - December 3, 2002; CBL Global Corp., Wholly-Owned Subsidiary of Trinity Companies, Inc., To Provide Awareness and Prevention Education Through Major Employers In Mining and Other Global Industries BERKELEY, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Trinity Companies, Inc. ( Trinity Companies ) (OTC: TTYC), a publicly-held Utah Corporation
Genetronics and Chiron Extend Collaborative Agreement to Explore Delivery of HIV Vaccine: PRNewswire - December 3, 2002; SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Genetronics Inc. (Amex: GEB; Toronto) announced today that it has extended a collaborative agreement with Chiron Corporation (Nasdaq: CHIR), Emeryville, CA to conduct additional experiments using Electroporation, Genetronics proprietary technology, to test an HIV DNA vaccine.
World Vision Named Lead Agency in Consortium Awarded $100 Million to Help Prevent Famine in Southern Africa: PRNewswire - December 3, 2002; WASHINGTON, Dec. 3 /PRNewswire/ -- The U.S. government has promised to World Vision and two other humanitarian organizations one of the largest emergency aid grants in history to help address the needs of people starving in southern Africa. The $100 million grant to World Vision, CARE, and Catholic Relief Services will
Mumbai AIDS and Health Education Gets Major Boost: PRNewswire - December 2, 2002; MUMBAI, Dec. 2 /PRNewswire Asia/ -- India s fight against AIDS received additional support today with a sponsorship from global reinsurer Swiss Re, under their Sharing Solutions programme, for an HIV education project in Mumbai. The project will be managed by the NGO PCI (Project Concern International) and locally impl
Healthy Russia 2020 Project Awarded to Consortium Led by Johns Hopkins Center for Communication Programs: Federal Grant of $25 Million Aims to Promote Healthier Russian Lifestyle: PRNewswire - December 2, 2002; BALTIMORE, Dec. 2 /PRNewswire/ -- The U.S. Agency for International Development (USAID) in Russia has awarded a group led by Johns Hopkins Bloomberg School of Public Health Center for Communication Programs (CCP) a $25 million grant to help improve the health of Russians, a population with a sobering health burden that
Romark Laboratories Announces FDA Approval of Drug for Children With Diarrhea Caused by Cryptosporidium and Giardia: First-Ever Cryptosporidium Treatment; First New Giardia Drug in More than 40 Years: PRNewswire - December 2, 2002; TAMPA, Fla., Dec. 2 /PRNewswire/ -- Romark Laboratories announced today that the United States Food and Drug Administration ( FDA ) has approved Alinia(TM) (nitazoxanide) for Oral Suspension for treatment of children with diarrhea caused by Cryptosporidium parvum and Giardia lamblia. Alinia is the first and only drug
Pfizer Inc and The Pfizer Foundation Announce New And Expanded HIV/AIDS Initiatives: Programs Increase Access to Medicines, Build Employee Awareness and Support HIV/AIDS Prevention and Education Organizations: PRNewswire - December 1, 2002; NEW YORK, Dec. 1 /PRNewswire-FirstCall/ -- Pfizer Inc and The Pfizer Foundation today announced new and expanded initiatives designed to address the growing threat to human health posed by the HIV/AIDS pandemic. On the second anniversary of their innovative Diflucan Partnership Program, Pfizer and the South African Min
Baltimore Area Clergy Launch HIV/AIDS Initiative on World AIDS Day: White House HIV/AIDS Policy Director is Guest Speaker: PRNewswire - December 1, 2002; BALTIMORE, Dec. 1 /PRNewswire/ -- Baltimore s interfaith community launched an HIV/AIDS awareness initiative on World AIDS Day, Sunday, December 1 at an ecumenical breakfast held at the New All Saints Roman Catholic Church, 4408 Liberty Heights Avenue. Clergy from across the city came together to pledge their support a
World AIDS Day, 2002: By the President of the United States of America: A Proclamation: PRNewswire - December 1, 2002; WASHINGTON, Dec. 1 /PRNewswire/ -- The following is a proclamation by the President: The HIV/AIDS pandemic has taken the lives of more than 20 million people and is projected to take millions more. On World AIDS Day, countries around the world are united to support the individuals, families, and communities affected by
Larry Kramer: Glaxo Patent on AZT is 'Murder!': Award-Winning Playwright, ACT UP Founder Supports GSK Patent Challenge: Lawsuit Seeks to Invalidate Patent on AZT, Other HIV Drugs.: PRNewswire - November 29, 2002; LOS ANGELES, Nov. 29 /PRNewswire/ -- Larry Kramer, the award-winning playwright and ACT UP (AIDS Coalition to Unleash Power) founder, has lent his powerful voice in support of a lawsuit seeking to invalidate the patent for the life-saving drug AZT (Retrovir(R) or zidovudine), the first AIDS drug. London-based
New Global Online Database of Programs Serving Children Affected By HIV/AIDS Announced by Pendulum Project, Children's AIDS Fund: PRNewswire - November 29, 2002; WASHINGTON, Nov. 29 /PRNewswire/ -- A new online database of programs serving children affected by HIV/AIDS around the world will debut on World AIDS Day December 1, 2002. Database listings will include grassroots programs throughout the world that provide care and support to children affected, infected and orphaned by
SHOWTIME Original Drama 'Behind The Red Door' Starring Kiefer Sutherland, Kyra Sedgwick and Stockard Channing to Air on Sunday, January 12 - SHOWTIME Supports Viacom's HIV/AIDS Initiative With AIDS Themed Film: PRNewswire - November 26, 2002; NEW YORK, Nov. 26 /PRNewswire/ -- SHOWTIME will premiere its latest original picture BEHIND THE RED DOOR on Sunday January 12 at 8:00 PM ET/PT. The film stars Golden Globe(R)-winning actor Kiefer Sutherland ( 24, Lost Boys, Young Guns and the SHOWTIME ORIGINAL PICTURE A Soldier s Sweetheart ), Kyra Sedgwick ( Something
Soft Economy Hardens Hearts for AIDS Crisis: More Americans Blame 'Lack of Money' for Inaction in Fight Against AIDS: PRNewswire - November 26, 2002; SEATTLE, Nov. 26 /PRNewswire/ -- Americans have little interest in helping children overseas orphaned by the AIDS pandemic, according to a national survey commissioned by World Vision, the international Christian humanitarian organization. While 41 percent said they might be open to supporting organizations addressing
Statement of IAVI's Seth Berkley, MD, in Response to the Latest UN HIV/AIDS Statistics: PRNewswire - November 26, 2002; NEW YORK, Nov. 26 /PRNewswire/ -- In advance of World AIDS Day, 1 December, the Joint United Nations Programme on HIV/AIDS and the World Health Organization have released the 2002 statistics on the global epidemic: By the end of this year, 5 million men, women and children worldwide will have become infected with HIV,
FDA Clears Use of GuideLines(TM) 6.0 Rules, Next-Generation Software To Help Predict HIV Drug Resistance - Interpretative Software Compares Results with Latest Medical Information: PRNewswire - November 26, 2002; TARRYTOWN, N.Y., Nov. 26 /PRNewswire/ -- Bayer Corporation, acting through its Diagnostics Business Group, today announced that the U.S. Food and Drug Administration ( FDA ) has granted clearance for GuideLines(TM) 6.0 Rules(1), the next-generation interpretative software used with the TRUGENE(TM) HIV-1 Genotyping Test
ViroLogic Announces Florida Medicaid Program Initiates Coverage Policy for HIV Drug Resistance Testing: Florida Is Second Largest HIV/AIDS Market In U.S.; 47 Out of 50 Medicaid Programs Now Cover Resistance Testing: PRNewswire - November 25, 2002; SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Florida Medicaid Program has initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing effective November 15, 2002. This brings the number of state Medicaid programs
Hemispherx Biopharma Invited to Present New Anti HIV Data at DART Conference: Phase IIB Clinical Trials of Strategic Treatment Intervention : Major Drug Development in Antiretroviral Research (DART) Conference 2002 in Naples, Florida, Tuesday, December 17: PRNewswire - November 25, 2002; PHILADELPHIA, Nov. 25 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB) announced today that it will present expanded new interim data from the Phase IIB HIV Clinical Trials of its RNA-based Ampligen(R) in Structured Treatment Interruption (STI), at the Drug Development in Antiretroviral Research (DART)
Are women more AIDS-conscious?: PRNewswire - November 25, 2002; - World AIDS day: 1 December 2002 Analysing the sales of a range of items that actively promote AIDS responsibility reveals that women would seem to be more proactive than their male counterparts when considering safe sex. Six times more women than men are buying underwear that has a secret pocket for a condom. The ran
Sir Elton John, Dave Matthews, Michelle Branch and Wyclef Jean Join Missy Elliott and a Host of Celebrities in Levi's(R) 'Staying Alive' Jacket Campaign : World AIDS Day Campaign Includes Specially Designed Levi's Jackets Listed On eBay(R) to Raise Funds and Awareness to Combat HIV/AIDS Globally: PRNewswire - November 22, 2002; SAN FRANCISCO, Nov. 22 /PRNewswire/ -- Several big name recording artists have joined the Levi s(R) Staying Alive Jacket campaign in an effort to raise funds and awareness to combat HIV/AIDS globally. The latest participants in the campaign are Dave Matthews and Michelle Branch. Matthews and Branch join a list of parti
Use of Boosted Saquinavir or Kaletra(TM) Results in HIV Suppression in Most Patients at 24 Weeks: PRNewswire - November 22, 2002; GLASGOW, Scotland, Nov. 22 /PRNewswire-FirstCall/ -- Data from the largest-ever study of boosted protease inhibitors demonstrated that a high proportion of HIV patients taking an investigational boosted saquinavir regimen (saquinavir 1000 mg with
GlaxoSmithKline/South Africa Picketed By Hundreds of Treatment Action Campaign (TAC) Activists : AIDS Healthcare Foundation Applauds Action By Advocates, Calls for Stepped Up Activism Against British AIDS Patent Pirates: PRNewswire - November 21, 2002; LOS ANGELES, Nov. 21 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the largest AIDS organization in the United States , today applauded two staged protests against British pharmaceutical giant GlaxoSmithKline (GSK)/ South Africa that were spearheaded by South Africa s Treatment Action Campaign (TAC).
BET Plans Special World AIDS Day Programming: Network's Popular News and Music Programming to Provide Public Awareness; Documentaries Will Focus on HIV/AIDS Epidemic Among African-American Population: PRNewswire - November 21, 2002; WASHINGTON, Nov. 21 /PRNewswire/ -- BET today announced its plans to provide special programming to coincide with World AIDS Day, which will be commemorated globally on Sunday, December 1. In keeping with its commitment to provide quality programming from an African-American perspective, BET will televise programs gear
48-Week Results for the SOLO Trial Comparing GW433908/R QD to Nelfinavir BID: Presented at International HIV Meeting: PRNewswire - November 21, 2002; GLASGOW, United Kingdom , Nov. 21 /PRNewswire/ -- Results of the SOLO trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) QD in antiretroviral
New Study Reports Alarming Rates of HIV and HCV Among African American and Latino American Drug Injectors : Former U.S. Surgeon General, Dr. Joycelyn Elders Backs Needle Exchange Programs to Fight Spread of HIV and Hepatitis C Among Drug Injectors: PRNewswire - November 21, 2002; NEW YORK, Nov. 21 /PRNewswire/ -- A study released this week found among drug injectors, African Americans are five times as likely to get HIV than whites and Latinos are one-and-a-half times as likely. The study also found that 50 to 80 percent of needle drug users become hepatitis C positi
FDA Approves Expanded Uses for Gen-Probe's HIV-1/HCV Assay: PRNewswire - November 20, 2002; SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) today announced that the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration has granted two new intended uses for Gen-Probe s licensed nucleic acid test (NAT) for the detection of human immunodef
Results of Clinical Trial Show Patients Who Switched from PI-based HIV/AIDS Regimen Maintained HIV Suppression and Improved Triglyceride Levels: PRNewswire - November 20, 2002; GLASGOW, Scotland, Nov. 20 /PRNewswire/ -- A new clinical study found that individuals switching from a protease inhibitor (PI)- based regimen to a PI- sparing, NNRTI-based regimen using VIRAMUNE(R)(nevirapine), sustained viral suppression and had improved triglyceride levels. Researchers also observed that individuals
Chemokine Modulators Likely to Generate Blockbuster Sales Through Use in Multiple Disease Drug Markets: HIV Market To Significantly Benefit From Chemokine Receptor Antagonists, According To New Report From Decision Resources: PRNewswire - November 20, 2002; WALTHAM, Mass., Nov. 20 /PRNewswire/ -- Decision Resources, one of the world s leading research and advisory firms for pharmaceutical and health care issues, forecast today that chemokine modulators are likely to generate blockbuster sales because of their use in multiple disease drug markets. By far the greatest poten
Chiron Signs Multi-Year Agreements with U.S Blood Collection Organizations: PRNewswire - November 19, 2002; EMERYVILLE, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today that multi-year agreements have been signed with the primary blood collection organizations in the U.S. for supply, service and support of Chiron s Procleix(TM) HIV-1/HCV Assay and System. Details of the agreements w
Chiron Signs Multi-Year Agreements with U.S Blood Collection Organizations: PRNewswire - November 19, 2002; EMERYVILLE, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today that multi-year agreements have been signed with the primary blood collection organizations in the U.S. for supply, service and support of Chiron s Procleix(TM) HIV-1/HCV Assay and System. Details of the agreements w
New Survey Finds Students 'Make the Grade' When it Comes to Smarter Sex, But More Education Still Needed: SmarterSex.org, New Sexual Health Site Just for College Students, Created to Fill Knowledge Gaps: PRNewswire - November 18, 2002; DENVER, Nov. 18 /PRNewswire-FirstCall/ -- New research about the sexual activities and attitudes of students ages 18-24 is offering a positive look at what is really happening behind closed doors. The Smarter Sex Survey, an online survey of more than 1,000 students, has surprising results: they take sex and monogamy se
Quest Diagnostics is the First Laboratory to Commercially Offer Improved HIV-1 Viral Load Test From Roche Diagnostics: PRNewswire - November 18, 2002; TETERBORO, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated, (NYSE: DGX), the nation s leading provider of diagnostic testing, information and services, announced today that it is the first reference laboratory to commercially offer Roche Diagnostics new, FDA- approved AMPLICOR HIV-1 MONITOR(R) Te
Second Pivotal Study Demonstrates Benefit of FUZEON(TM) Across Range of Treatment-Experienced HIV Patients - Separate Study Shows Subcutaneous Administration Manageable for Most Patients at 24 Weeks: PRNewswire - November 18, 2002; GLASGOW, Scotland, Nov. 18 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced data from a second pivotal Phase III study (TORO 2) demonstrating that FUZEON(TM) (enfuvirtide), in combination with other antiretrovirals, provided benefit to treatment-experienced HIV patients at 24 weeks rega
Magic Johnson Brings Message Of Hope To African Americans With HIV: PRNewswire - November 15, 2002; RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- Earvin Magic Johnson is teaming up with GlaxoSmithKline (GSK) to bring hope, encouragement and awareness about HIV/AIDS to the African-American community, which has experienced a steep rise in the incidence of the disease in the last decade. Johnson and GSK anno
ViroLogic Signs Preferred Provider Agreement and Equity Agreement with Pfizer: PRNewswire - November 14, 2002; SOUTH SAN FRANCISCO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed a preferred provider agreement with Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, ViroLogic becomes Pfizer s preferred supplier for HIV resistance testing technology and
ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to Monitor/Audit Trials, Selikoff Center to Conduct Trials: PRNewswire - November 14, 2002; YONKERS, N.Y., Nov. 14 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it has initiated the single dose safety study which is the first phase of three Product R clinical trials in Israel . The Company also announced that it has retained Quintiles Transnational Cor
Kaleidos Pharma, Inc. Announces Collaboration with the NIH to Investigate The Use of TGF alpha in the Treatment of AIDS: PRNewswire - November 13, 2002; SEATTLE, Nov. 13 /PRNewswire/ -- Kaleidos Pharma, Inc., today announced a collaboration with the Division of AIDS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). Under the terms of the agreement, NIH researchers will conduct a non-human primate study to evaluate the po
Pharmacor Receives U.S. Patent for Next-Generation anti-HIV Protease Inhibitor: PRNewswire - November 13, 2002; MONTREAL, Nov. 13 /PRNewswire/ - Pharmacor Inc. has been issued U.S. patent application no. 10/143,095, relating to its antiretroviral program. The small-molecule compounds described in the patent, entitled Urea derivatives as HIV aspartyl protease inhibitors , are next-generation anti-HIV lead molecules that demonstra
Nation's First Health Care Center Targeted to Injection Drug Users Opens in New York City -Injection Drug Users Account for 30 Percent of All New HIV/AIDS Cases in the U.S.: PRNewswire - November 13, 2002; NEW YORK, Nov. 13 /PRNewswire/ -- Positive Health Project, a New York City syringe exchange program, and Diversified Health Systems Management, Inc., today announced the opening of Positive Health Care, the nation s first comprehensive health care center targeting high-risk clients, including current and former injecti
The Advertising Council and the United Nations Foundation Launch National Campaign to Raise Awareness of the Global AIDS Epidemic: PRNewswire - November 12, 2002; NEW YORK, Nov. 12 /PRNewswire/ -- The United Nations Foundation, in partnership with The Advertising Council, announced the launch of a new public service advertising (PSA) campaign designed to raise national awareness of the global AIDS epidemic and encourage all Americans to get involved in the fight against AIDS.
Gen-Probe Receives FDA Approval for Its Hepatitis C Virus (HCV) Qualitative Assay: PRNewswire - November 8, 2002; -- Most Sensitive Assay to Be Approved for Qualitative Detection Of HCV to Be Marketed by Bayer Diagnostics - SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO), an established leader in molecular diagnostics based on its patented nucleic acid testing (NAT) technologies, today announced t
Preventing HIV Feels Good in New Social Marketing Campaign Targeting Positives: PRNewswire - November 7, 2002; SAN FRANCISCO, Nov. 7 /PRNewswire/ -- I have HIV, and I have sex is the opening line of a bold new installment of the groundbreaking HIV STOPS WITH ME public health prevention campaign. Reaching out to people already infected with HIV, the campaign is due to launch this week on television and in print in San Francisco.
EngenderHealth Awarded HIV/AIDS Health Literacy Grant From The Pfizer Foundation: PRNewswire - November 7, 2002; NEW YORK, Nov. 7 /PRNewswire/ -- EngenderHealth today announced that it has been awarded a $178,266 grant under The Pfizer Foundation s newly introduced International HIV/AIDS Health Literacy Grants program. This grant will enable EngenderHealth to start its project, Building a Common Literacy: Creating Bridges between
FDA Approves New 20-Minute Rapid HIV Test: PRNewswire - November 7, 2002; -- Magic Johnson, Congresswoman Loretta Sanchez, AIDS Healthcare Foundation Applaud Action on Potential Life-saving Tool: Broad Coalition of Public Officials, Health Organizations, AIDS Groups Now Call for Widespread Availability of Test WASHINGTON, Nov. 7 /PRNewswire/ -- Health and Human Services Secretary Tommy Thomp
Ghana Launches National Program to Encourage Compassion and Support For People Living with HIV/AIDS - Muslim and Christian Leaders to Help Implement Phase 2 of Stop AIDS, Love Life: PRNewswire - November 6, 2002; ACCRA, Ghana , Nov. 6 /PRNewswire/ -- Muslim and Christian religious leaders will foster support and compassion for those living with HIV/AIDS under a new program launched today in Ghana, where approximately a half- million people are living with the virus that causes AIDS. Reach Out, Show Compassion for people living
Gates Foundation, BIO Global Health Forum Features International Health Experts: PRNewswire - November 5, 2002; WASHINGTON, Nov. 5 /PRNewswire/ -- The Biotechnology Industry Organization (BIO) today announced that Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and David L. Heymann, MD, executive director of communicable diseases for the World Health Organization (WHO),
NASA's Quest to Determine How Space Affects the Shelf-Life of Medications Is Among the Topics Presented at This Year's Annual Meeting of the American Association of Pharmaceutical Scientists: PRNewswire - November 4, 2002; -- Annual Meeting Makes Its International Debut in Toronto, Ontario, Canada on November 10-14; More than 7,500 Scientists to Attend ARLINGTON, Va., Nov. 4 /PRNewswire/ -- From effects of space on an astronaut s medications to a young scientist s dream of creating a healthier world for all races, the 2002 American Assoc
Brazil Orders Four Million FC Female Condoms - Prevention Program Continues to Expand: PRNewswire - November 4, 2002; CHICAGO, Nov. 4 /PRNewswire-FirstCall/ -- The Female Health Company (OTC Bulletin Board: FHCO) today announced that it signed a contract with the Ministry of Health of Brazil to provide four million FC Female Condoms for the Ministry s groundbreaking National AIDS Program. Under the terms of the contract, two million u
Coviracil(R) NDA for the Treatment of HIV Disease Accepted by the Food and Drug Administration: PRNewswire - November 4, 2002; DURHAM, N.C., Nov. 4, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that the U.S. Food and Drug Administration ( FDA ) has notified the Company that its New Drug Application (NDA) for marketing approval of Coviracil for the treatment of HIV disease has been accepted for fi
Study Shows New Drug Reduced Morbidity And Mortality Associated With Cryptosporidiosis In Malnourished Children: PRNewswire - November 4, 2002; TAMPA, Fla., Nov. 4 /PRNewswire/ -- A study published in the November 2, 2002 issue of the British journal, The Lancet, showed that a new drug, nitazoxanide, significantly reduced the duration of diarrhea and the rate of death in malnourished children with Cryptosporidium infection. Cryptosporidium is a waterborne prot
Compounds with Potential Use in Treatment of Cancer, HIV and Hepatitis C Donated to University of Arizona Foundation by Procter & Gamble: PRNewswire - November 4, 2002; -- University of Arizona College of Pharmacy, Arizona Cancer Center to Lead Research TUCSON, Ariz., Nov. 4 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) today donated to the University of Arizona (UA) Foundation 33 patents and accompanying intellectual property related to a portfolio of compounds that hav
Norzyme(TM) Clinical Trials On HIV-AIDS Patients Underway: National Institutes Of Health (NIH) Grants Of $1.6 Million Funding Study: PRNewswire - November 4, 2002; CHICAGO, Nov. 4 /PRNewswire/ -- Norzyme, Inc., developer of therapeutic drug monitoring technology for use at point-of-care, has launched clinical trials for its Levoprin-ZG(TM) product, developed to aid in the disease management of HIV-AIDS patients. Five universities are participating in the study, titled Measurement
Biosyn, Inc. Announces $10 Million Grant from National Institutes of Health: PRNewswire - November 4, 2002; HUNTINGDON VALLEY, Pa., Nov. 4 /PRNewswire/ -- Biosyn, Inc. announced today that the company, along with five collaborating partners, has been awarded a $10 million grant from the National Institutes of Health (NIH) for the development of a potent HIV-inhibiting compound, Cyanovirin-N, as a microbicide to prevent the s
Bush Administration Awards $12 Million to Provide Permanent Housing and Services to Thousands Living With HIV/AIDS: PRNewswire - October 31, 2002; WASHINGTON, Oct. 31 /PRNewswire/ -- Thousands of people with HIV/AIDS and their families will receive permanent housing and supportive services as a result of $12 million in grants announced today by Housing and Urban Development Secretary Mel Martinez. The renewal grants are part of HUD s Housing Opportunities for Per
L.A. County Supervisor Don Knabe, Congresswoman Jane Harman to Cut Ribbon as AIDS Healthcare Foundation, Pathways Join Forces in Grand Opening of New Redondo Beach HIV/AIDS Healthcare Center: PRNewswire - October 31, 2002; Partnership Between Nation s Largest AIDS Organization, Respected Local Social Service Provider Offers Region s HIV/AIDS Patients Improved Access to Quality Care, Services in South Bay REDONDO BEACH, Calif., Oct. 31 /PRNewswire/ -- In an effort to better reach some under-served Los Angeles County residents with quality
Top Scientists Find Cure For CytRx: PRNewswire - October 30, 2002; LOS ANGELES, Oct. 30 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR) announced today the results of the company s first Scientific Advisory Board (SAB) meeting. The meeting was chaired by Dr. Louis Ignarro, 1998 Nobel Laureate in medicine, and took place on Thursday, October 17th in Los Angeles, California. The SAB of
ChevronTexaco Sponsors 'A Day in the Life of Africa' Project - All Publishing Profits From Book to Support HIV/AIDS Education Fund Programs in Africa: PRNewswire - October 30, 2002; SAN FRANCISCO, Oct. 30 /PRNewswire/ -- ChevronTexaco Corp. (NYSE: CVX) today welcomed the official launch of A Day in the Life of Africa, the latest release in the best-selling A Day in the Life photo documentary series. ChevronTexaco is an underwriting partner of the project -- which includes a book, DVD documentary a
American TeleCare(R), Inc. Announces Partnership with New York City Health & Hospitals Corporation -- HHC Health & Home Care: PRNewswire - October 28, 2002; EDEN PRAIRIE, Minn., Oct. 28 /PRNewswire/ -- American TeleCare, Inc. (ATI) announced today that HHC Health & Home Care, a division of New York City Health & Hospitals Corporation, has implemented the first home telehealth program that targets patients who are HIV positive. In March 2002, HHC purchased 59 of ATI
Life OUTside, America's New, Syndicated, Gay Radio-Newsmagazine, Joins Growing Ranks of Gay Programs Available Via Mainstream Media: PRNewswire - October 28, 2002; -- News, Solid Reporting and Dateline Format Drawing Gay and Straight Listeners Alike To Life OUTside on 70 Radio Stations Nationwide Plus Internet CHICAGO, Oct. 28 /PRNewswire/ -- Once relegated to local community newspapers, during the past decade, gay-themed programming and media have grown exponentially to now reac
Discovery Health Channel Airs Special Programming on World AIDS Day: December 1: PRNewswire - October 28, 2002; -- Actor James Woods Hosts Program Featuring Children Who Relate Their Personal Experiences With HIV/AIDS; Another Examines the Impact of this Devastating Epidemic on Our Society BETHESDA, Md., Oct. 28 /PRNewswire/ -- Although the growth of the ongoing AIDS epidemic has wrought a terrible physical and emotional toll, m
Bill & Melinda Gates Foundation Grant Awarded to Johns Hopkins To Explore Novel Interventions to Control HIV-Related Tuberculosis: PRNewswire - October 28, 2002; SEATTLE and BALTIMORE, Oct 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation will contribute $3 million to the Johns Hopkins University School of Medicine for the development of community-based preventive strategies to control tuberculosis (TB) in areas around the world with severe HIV epidemics. The grant wi
Bill & Melinda Gates Foundation Grant to Evaluate Once-Daily Antiretroviral As a Potential Method of HIV Prevention: PRNewswire - October 28, 2002; SEATTLE and RESEARCH TRIANGLE PARK, N.C., Oct. 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today that it has awarded Family Health International (FHI) a $6.5 million, three-year grant for a multinational clinical trial to evaluate an antiretroviral treatment as a novel approach to HIV preventio
Multiple Characteristics of HAART Affect Adherence; Pill Count Has the Greatest Impact on Adherence, Survey Reports: PRNewswire - October 26, 2002; At-A-Glance -- 299 HIV+, treatment-experienced people participated in the survey -- Multiple factors impact a patient s adherence to a HAART treatment regimen exactly as prescribed. -- Total number of pills in a regimen has the greatest impact on adherence of 10 attributes studied in a survey on treatment adherence.
Nationwide Survey Shows 80% of HIV-positive Patients Report Symptoms of Depression and Anxiety: PRNewswire - October 25, 2002; -- HIV Infection, Street Drugs and HIV Medications Cited as Leading Causes - CHICAGO, Oct. 25 /PRNewswire/ -- Key findings of a national physician and patient survey conducted by the International Association of Physicians in AIDS Care (IAPAC) demonstrate a strong link between HIV infection and the mental health of pat
Business, Media, Non-Government Organizations & Charitable Foundations Form Unprecedented Partnership to Make Globally Televised World AIDS Day Concert: PRNewswire - October 25, 2002; -- Sean P. Diddy Combs to Perform in Cape Town & Michelle Branch in Seattle as Part of HIV/AIDS Awareness Concerts To Premiere on MTV Globally as 90-Minute Special on World AIDS Day -- More Than 60 Broadcasters Worldwide Confirmed to Air Concert & Other HIV/AIDS Awareness Programming Rights Free CAPE TOWN,
ALR Technologies Taking Medication Non-Compliance Message to Government and Health Insurance Officials: PRNewswire - October 25, 2002; -- Medication Noncompliance Increases Health Problems and Escalates Healthcare Costs WINSTON-SALEM, N.C., Oct. 25 /PRNewswire-FirstCall/ -- ALR Technologies (OTC Bulletin Board: ALRT), manufacturer of an affordable, easy-to-use medication reminder called the ALRT Med Reminder, announced at a meeting this week in Winsto
New Study Evaluates the Effectiveness of VALTREX(R) Caplets For Suppression Of Genital Herpes In HIV-Infected Persons: PRNewswire - October 25, 2002; - VALTREX Prolonged Length of Time To First Recurrence of Genital Herpes CHICAGO, Oct. 25 /PRNewswire/ -- Twice daily treatment with VALTREX(R) (valacyclovir HCl) caplets is effective in suppressing genital herpes recurrences in HIV-infected patients, according to data presented at the Infectious Diseases Society of Am
New 20-Minute Rapid HIV Test Nears FDA Approval: Broad Coalition of Public Health Officials, Health Organizations, AIDS Groups Call for Widespread Availability of Potential Life-Saving Tool: PRNewswire - October 24, 2002; LOS ANGELES, Oct. 24 /PRNewswire/ -- A broad, growing coalition of public health officials, health organizations, and HIV/AIDS groups are calling for widespread availability of new rapid HIV tests through a waived status under the Clinical Laboratories Improvement Act (CLIA). Supporters include President Bush s Advisor
102.9 WMGK, Philadelphia, Will Exhibit Works of Art Created by Popular Musicians, Singers and Songwriters at The Shops at Liberty Place: PRNewswire - October 23, 2002; -- The Month-Long 102.9 WMGK Classic Rock Art Show and Silent Auction Opens To The Public on Friday, November 15 and Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation PHILADELPHIA, Oct. 23 /PRNewswire/ -- WMGK (102.9FM/Philadelphia) will showcase a never-before seen collection of original art and lithographs,
Zengen, Inc. Announces Investigational New Drug Filing To Treat Vaginal Yeast Infection: PRNewswire - October 23, 2002; -- Company s Proprietary Peptide Technology Offers Potential Alternative to Standard Treatment Regimens WOODLAND HILLS, Calif., Oct. 23 /PRNewswire/ -- Zengen, Inc. announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for CZEN 002, one of the Company
Chiron Corporation Provides Clinical Pipeline Update: Company Announces Discontinuation of SILCAAT and HBV-MF59 Trials And PA-1806 Program: PRNewswire - October 23, 2002; -- Information for SILCAAT Patients and Clinicians Available Toll Free At 1-866-874-3153 EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) announced today decisions on three clinical development programs. Chiron is stopping SILCAAT, a Phase III study for recombinant human interleuk
Delta Dental Plan of Minnesota Study Suggests Regular Dental Visits Benefit Oral Health of HIV Patients; Study is Lead Story in October Issue of JADA: PRNewswire - October 23, 2002; EAGAN, Minn., Oct. 23 /PRNewswire/ -- Regular dental visits may help maintain better oral health in people with the Human Immunodeficiency Virus (HIV), suggests a study conducted by Delta Dental Plan of Minnesota researchers and published as the cover story in the October issue of the Journal of the American Dental Ass
The Only Oral Anabolic Agent Indicated for the Treatment of Involuntary Weight Loss - New 10mg OXANDRIN(R) Tablets Now Available ...: PRNewswire - October 22, 2002; - More Convenient Dosage of OXANDRIN May Enhance Patient Compliance ISELIN, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Today Bio-Technology General Corp. (Nasdaq: BTGC) announced the availability of the new 10mg strength of OXANDRIN(R) (oxandrolone, USP - CIII) a treatment for involuntary weight loss which can be associat
Remarks by the President on Prescription Drugs: PRNewswire - October 21, 2002; WASHINGTON, Oct. 21 /PRNewswire/ -- The following are remarks by the President on Prescription Drugs: The Rose Garden 8:33 A.M. EDT THE PRESIDENT: Good morning. For more than a year, the Federal Trade Commission has investigated delays and abuses in the process of bringing generic drugs to the market. I have reviewed t
Parker Hughes Develops New AIDS Drug; Stampidine Effective Against Drug Resistant HIV: PRNewswire - October 21, 2002; ROSEVILLE, Minn., Oct. 21 /PRNewswire/ -- A new powerful drug against AIDS, known as STAMPIDINE, was developed at the Parker Hughes Center for Clinical Immunology. The effectiveness of this drug was tested first in the test tube against drug-resistant AIDS virus isolates from 29 different HIV- infected individuals. Thi
VaxGen's Phase III Trial in Thailand Clears Final Scheduled Safety Review: PRNewswire - October 21, 2002; BRISBANE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- The independent board that oversees VaxGen , Inc. s clinical trials completed the final safety and conduct review of the company s Phase III trial in Thailand and once again concluded that the study was being conducted appropriately and that VaxGen s AIDS vaccine cand
ViroLogic and Surveillance Data, Inc., Partner to Create New HIV Market Data Products: PRNewswire - October 21, 2002; SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) and Surveillance Data, Inc. (SDI), announced today that the companies have signed an agreement to create a new line of HIV market research products based on data collected through ViroLogic s HIV resistance testing and therapy
Kawasumi America Receives FDA 510 (K) Clearance on Needle Safety Device: PRNewswire - October 18, 2002; - K-Shield Protection Device Provides Cost-Effective Mechanism for OSHA Needle Stick Safety Compliance TAMPA, Fla., Oct. 18 /PRNewswire/ -- Kawasumi Laboratories America, Inc. has received FDA 510 (k) clearance to market a needle safety device to protect oncology clinicians from Huber needle stick injuries incurred whi
The Medical Institute for Sexual Health: Scientific Review of Condom Effectiveness Research Reveals Condoms Provide Inadequate Risk Reduction For Sexually Transmitted Diseases: PRNewswire - October 16, 2002; WASHINGTON, Oct. 16 /PRNewswire/ -- A new scientific report released today reveals that condoms, even when used 100 percent of the time, fail to reduce the risk of some of the most common and potentially dangerous sexually transmitted diseases (STDs) to an acceptable level. Sex, Condoms, and STDs: What We Now Know, rel
Immusol Chief Scientific Officer, Flossie Wong-Staal, Ph.D., Named One of Top 50 Women Scientists: PRNewswire - October 15, 2002; SAN DIEGO, Oct. 15 /PRNewswire/ -- Immusol, The Inverse Genomics(TM) Co., announced that Discover Magazine has recognized Dr. Flossie Wong-Staal, Immusol s Chief Scientific Officer and Vice President of Genomics, as one of 50 most extraordinary women scientists across all disciplines. Selection of the top women scienti
Pharmacor Discovers New Class of Compounds for the Treatment of Drug-Resistant HIV/AIDS: PRNewswire - October 15, 2002; MONTREAL, Oct. 15 /PRNewswire-FirstCall/ - Pharmacor announces the discovery of a new class of drug-like compounds in its battle against drug- resistant HIV. The exceptional characteristic of these compounds is that they are significantly more active against protease-inhibitor (PI) resistant strains than against the co
ALR Technologies Medication Reminders Benefit Treatment for AIDS Patients: PRNewswire - October 15, 2002; WINSTON-SALEM, N.C., Oct. 15 /PRNewswire/ -- Patients undergoing treatment for the HIV virus have benefited from a new medication reminder that prompts them to take their medications on time, as prescribed, according to feedback from physicians who have given reminders to their patients. The positive, anecdotal results
AIDS Healthcare Foundation's Anti-Trust Complaint Amended to Include GSK's Blockbuster AIDS Drugs Combivir & Trizivir; Fraud During Patent Process Used to Procure Invalid Patents on AZT and Other Subsequent HIV Drugs: PRNewswire - October 15, 2002; - Nation s Largest AIDS Organization Discovers Glaxo Smoking Gun: British Drug Maker Lied to Get AZT Patent NEW YORK, Oct. 15 /PRNewswire/ -- The largest AIDS organization in the United States today announced that it has filed an amended federal anti-trust complaint against British-owned
Global Health Action Makes Inroads Into China: PRNewswire - October 15, 2002; - Global Health Action Collaborates With Chinese Health and Government Agencies to Address Domestic Abuse, HIV/AIDS Infection and Women s Reproductive Health Issues ATLANTA, Oct. 15 /PRNewswire/ -- Global Health Action (GHA), a nonprofit health education and leadership and management development organization headquarte
ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic Leukemia Cells in Laboratory Cultures: PRNewswire - October 11, 2002; - Findings Presented at Meeting of the American Association for Cancer Research Show That Product R Induces Differentiation of a Human Promyelocytic Leukemia Cell Line YONKERS, N.Y., Oct. 11 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that the Company s peptide nuc
ViroLogic Announces Study Published in Journal of AIDS Supports Use Of PhenoSense GT Combination Assay: PRNewswire - October 11, 2002; - 1,400-Patient Sample Study Demonstrates Phenotypic and Genotypic Assays Provide Complementary Information Critical for Optimum Treatment SOUTH SAN FRANCISCO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that study results published in the current issue of the Journal of Acq
FUZEON(TM) Granted Priority Review Status by U.S. FDA - First HIV fusion inhibitor will have a target six month review period -: PRNewswire - October 11, 2002; NUTLEY, N.J. and DURHAM, N.C., October 11 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced that the U.S. Food and Drug Administration ( FDA ) has notified the companies that the New Drug Application (NDA) for FUZEON(TM) (generic: enfuvirtide, formerly known as T-20) is fileable and has
Planning Reduces Impact of HIV on Mother and Baby: PRNewswire - October 10, 2002; LAS VEGAS, Oct. 10 /PRNewswire/ -- Women infected with HIV who develop a treatment plan with both their pediatrician and obstetrician during pregnancy reduce the impact of the virus on themselves and their unborn baby, Ronald J. Librizzi, D.O., an osteopathic obstetrician and gynecologist, reported at the American Oste
FDA Grants URRMA Biopharma IDE Approval For Anti-R7V Diagnostic Kit as Determinant For Progressor / Non-Progressor to Aids: PRNewswire - October 10, 2002; MONTREAL, Oct. 10 /PRNewswire/ - URRMA Biopharma Inc. ( URRMA ) is pleased to announce the US Food and Drug Administration ( FDA ) has granted approval of URRMA s Investigational Device Exemption (IDE) application for the Anti-R7V Diagnostic Kit. This is equivalent to a Phase II in the more commonly used terminology pe
Chimerix, Inc. Announces Appointment of Expert In Antiviral Discovery and Development as CEO - Company Currently Developing an Oral Drug for Smallpox Infections -: PRNewswire - October 9, 2002; SAN DIEGO, Oct. 9 /PRNewswire/ -- Chimerix, Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today announced the appointment of George Painter, Ph.D. as company President and CEO. Dr. Painter has twenty-four years of experience in the discovery and develo
Viacom and Kaiser Family Foundation to Launch Comprehensive Media Campaign to Fight HIV/AIDS: PRNewswire - October 9, 2002; - Worldwide Initiative to Foster HIV/AIDS Awareness and Prevention Through PSAs, Television and Radio Programming, and Outdoor, Print and Online Content NEW YORK, Oct. 9 /PRNewswire/ -- Viacom Inc. and the Henry J. Kaiser Family Foundation today announced a comprehensive global media campaign beginning January 6, 2003
Bill Gates to Visit India on HIV/AIDS Mission: PRNewswire - October 6, 2002; SEATTLE, Oct. 6 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced that its co-founder, Bill Gates, will visit India next month to lead a foundation delegation that will see first-hand some of the challenges and exemplary initiatives underway to prevent the transmission of HIV. During his trip, Ga
Gen-Probe Receives Contract Funding From the National Heart, Lung And Blood Institute to Initiate Development of a Nucleic Acid Screening Test for West Nile Virus: PRNewswire - October 3, 2002; SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) an established leader in molecular diagnostics based on its patented nucleic acid testing (NAT) technologies, today announced that it has received $1.0 million from the National Heart, Lung and Blood Institute (NHLBI) of the National Inst
Two Historic HIV/AIDS Awareness Concerts to Take Place in Cape Town with Alicia Keys, & Seattle with Missy Elliott & Dave Matthews to Premiere on MTV Globally as 90-Minute Special on World Aids Day, December 1st: PRNewswire - October 3, 2002; - MTV, Levi s(R) Brand, Bill & Melinda Gates Foundation, Paul G. Allen Charitable Foundation, Population Services International s YouthAIDS & UNAIDS Form Unprecedented HIV/AIDS Awareness Partnership For Youth - All HIV/AIDS Awareness Programming & PSAs Available Rights Free to All Broadcasters Worldwide
U.S. Government Bars Unfair Drug Marketing Practices: AIDS Healthcare Foundation Urges Lower Drug Prices to Reflect Reduced Marketing Costs: PRNewswire - October 2, 2002; - As Government Limits Pharmaceutical Marketing Practices That Skirt Federal Fraud and Abuse Laws, Nation s Largest AIDS Organization Demands That Drug Price Reductions Accompany New Regulations LOS ANGELES, Oct. 2 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest specialized provider of HIV/AIDS m
SLIL Biomedical Announces Publication of Study on Its Proprietary 'Sequential Pathogenesis' Technology in October Issue of Cancer Research: PRNewswire - October 2, 2002; MENLO PARK, Calif., Oct. 2 /PRNewswire/ -- SLIL Biomedical Corp. today announced the publication of seminal Sequential Pathogenesis research, conducted by UCSF scientists, SLIL Biomedical researchers and academic collaborators, in the October issue of Cancer Research. The study found that macrophages, normally key immu
EraGen Biosciences' Nucleic Acid Technology Validated by FDA Approval of Bayer Diagnostics' VERSANT(R) HIV-1 RNA 3.0 Assay: PRNewswire - October 2, 2002; MADISON, Wis., Oct. 2 /PRNewswire/ -- EraGen Biosciences, a growing life science company, commented today on the relationship between its AEGIS(TM) nucleic acid technology and the recent US Food and Drug Administration ( FDA ) approval of Bayer Diagnostics VERSANT(R) HIV-1 RNA 3.0 Assay (bDNA). The Versant(R) Assay ha
Abbott Laboratories' Kaletra(R) (lopinavir/ritonavir) Attains Status As Most-Prescribed Protease Inhibitor for the Treatment of HIV: PRNewswire - October 2, 2002; ABBOTT PARK, Ill., Oct. 2 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: ABT) Kaletra (R) ( lopinavir / ritonavir ) has become the most-prescribed protease inhibitor (PI) as part of a treatment regimen for HIV in th
Nastech Reacquires Nascobal(R) (Cyanocobalamin, USP) Gel From Schwarz Pharma And Signs Contract Sales Agreement With Cardinal Health: PRNewswire - October 1, 2002; BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced it has reacquired all product, patent, trademark, licensing and regulatory rights for Nascobal(R) in the United States from Schwarz Pharma. Under terms of the acquisition agreement, Nastech will pay Schwarz a t
Serono Announces Positive Results of Serostim(R) Clinical Trial for Treatment of HIV-Related Metabolic Complication: PRNewswire - September 30, 2002; - Findings Also Suggest Reduction in Cardiovascular Risk Factors Associated with Condition ROCKLAND, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Serono S.A. (virt-x: SEO and NYSE: SRA) announced 24-week results from a completed clinical trial of Serostim (R) [somatropin (rDNA origin) for injection] evaluating the trea
VIRACEPT(R) Appears to be Generally Well Tolerated In Hepatitis-C Co-Infected Patients: PRNewswire - September 30, 2002; SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Data presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy in San Diego reveal that for patients co-infected with Hepatitis-C (HCV) and HIV, VIRACEPT(R) (nelfinavir mesylate) is generally well tolerated. The retrospective analysis, con
ViroLogic Studies Presented at ICAAC Highlight Benefits Of Its HIV Drug Resistance Technology - Company Also Launches Comprehensive Professional Education Program: PRNewswire - September 30, 2002; SOUTH SAN FRANCISCO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced that results of four studies demonstrating the benefits of its HIV drug resistance products and technologies were presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Achillion Pharmaceuticals Presents at ICAAC In Vitro Data Showing Anti-HIV Activity of a New Class of Compounds Against a Novel HIV Target: PRNewswire - September 30, 2002; - Representative Lead Pre-clinical Compound Developed To Combat HIV Drug Resistance Using Novel Target SAN DIEGO, Calif., Sept. 30 /PRNewswire/ -- Achillion Pharmaceuticals announced the development of a new class of compounds that inhibits a broad spectrum of drug-resistant HIV strains by targeting a novel virus prote
Achillion Pharmaceuticals and Beth Israel Deaconess Investigator Present Results of a Phase 1/2 Clinical Trial Demonstrating Potent Antiviral Activity Of New Anti-HBV Agent at ICAAC: PRNewswire - September 28, 2002; SAN DIEGO, Sept. 28 /PRNewswire/ -- Demonstrating encouraging advances in the treatment of chronic hepatitis B virus (HBV) infection, researchers at Beth Israel Deaconess today presented the first clinical data for Beta-L-Fd4C (ACH-126,443), Achillion Pharmaceuticals novel L-nucleoside. In the blinded, placebo contro
Data Show Bristol-Myers Squibb's Investigational Protease Inhibitor Atazanavir Provided Antiviral Effect Comparable to SUSTIVA(R) In Treatment-Naive HIV/AIDS Patients: PRNewswire - September 28, 2002; SAN DIEGO -- A study presented today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, California showed that a regimen containing the investigational protease inhibitor atazanavir provided antiviral effect comparable to a standard-of-care regimen containing SUSTIVA(R) (
New Data Demonstrate Benefit of FUZEON(TM) in Combination Therapy Across Range of Treatment-Experienced HIV Patients - Patients See Improvement Regardless of Treatment History: PRNewswire - September 28, 2002; SAN DIEGO -- Roche and Trimeris (NASDAQ: TRMS) today announced new data from a Phase III pivotal study demonstrating that regardless of patient demographics or treatment history, FUZEON(TM) (generic: enfuvirtide, formerly known as T-20) in combination with other antiretrovirals provided benefit to treatment-experienced
GlaxoSmithKline Drug Discovery and Development Award 2002 - Six Researchers Share $500,000 Award for Work on HIV/AIDS Treatment Breakthroughs: PRNewswire - September 27, 2002; SAN DIEGO, Sept. 27 /PRNewswire/ -- Six HIV and AIDS researchers will split $500,000 as this year s recipients of the GlaxoSmithKline (GSK) Drug Discovery and Development Award. The unrestricted research award program is funded by GSK to support independent, innovative and novel research in the development of HIV/AIDS
New Study Evaluates Suppressive Therapy With VALTREX(R) Caplets for the Reduction of Transmission of Genital Herpes: PRNewswire - September 27, 2002; SAN DIEGO -- According to study data presented at the 42nd ICAAC, the Interscience Conference on Antimicrobial Agents and Chemotherapy, once-daily suppressive therapy with VALTREX(R) (valacyclovir HCl) caplets reduced transmission of symptomatic genital herpes (a visible outbreak) by 77 percent in healthy heterosexual
New Protease Inhibitor Held HIV at Undetectable Levels For Four Years: PRNewswire - September 27, 2002; SAN DIEGO -- A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir / ritonavir ( Kaletra (R)) suppressed HIV to undetectable levels and was well tolerated through four years of treat
Bristol-Myers Squibb Early Access Program Can Provide Investigational Protease Inhibitor Atazanavir for Eligible Patients With HIV: PRNewswire - September 27, 2002; PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE: BMY) has started enrolling patients in an early access program to provide the investigational protease inhibitor, atazanavir, to eligible patients infected with HIV. An early access program (EAP) provides medicines to eligible patients in need of alternative therap
Once-Daily Coviracil(R) Regimen Superior to Zerit(R) in FTC-301 Clinical Trial; Triangle Pharmaceuticals, Inc. Presents Coviracil Data at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): PRNewswire - September 27, 2002; SAN DIEGO -- Triangle Pharmaceuticals, Inc. (NASDAQ: VIRS) presented data at the Late Breaker Session at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which showed that Coviracil (emtricitabine) was statistically superior to Zerit (
Mymetics Corporation Presents Promising New AIDS Therapy Research Results at ICAAC: PRNewswire - September 27, 2002; ANNAPOLIS, Md. -- Mymetics Corporation (BULLETIN BOARD: MYMX) today presented preclinical data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on two novel gp41-derived peptide candidates that demonstrate potent inhibition of HIV in vitro. Both peptides were developed to disrupt a phenom
New Data Shows Better Lipid Safety Profile of Boosted Saquinavir vs. Boosted Indinavir: PRNewswire - September 27, 2002; SAN DIEGO -- Roche today announced results of two studies examining the lipid safety profile of twice-daily boosted saquinavir (1000 mg saquinavir with 100 mg ritonavir ) for HIV. Data from the first head-to-head study of boosted
Phase III, 24-Week Results for the NEAT Trial Comparing GW433908 (908) to Nelfinavir: Presented At ICAAC: PRNewswire - September 27, 2002; SAN DIEGO -- Results of the NEAT trial, an open-label, multi-center study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-naive patients versus nelfinavir (NFV, Viracept (R)), were presented here today at the 42nd Interscience Conference on A
The Coca-Cola Africa Foundation and Coca-Cola Bottlers in Africa Create HIV/AIDS Healthcare Program: PRNewswire - September 26, 2002; - Program Designed to Expand Employee Healthcare to Include AIDS Testing And Drug Treatment That Will Start in Southern and Eastern Africa MANZINI, Swaziland , Sept. 26 /PRNewswire/ -- The Coca-Cola Africa Foundation announced today that it is joining with Coca-Cola s 40 bottlers in Africa to help them expand their emp
ViroLogic Announces Significant Presence at 42nd Interscience Conference On Antimicrobial Agents and Chemotherapy: PRNewswire - September 26, 2002; SOUTH SAN FRANCISCO, Calif., Sept. 26 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that four presentations related to its novel drug resistance products and technology will be made at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place at the San Di
PharmAccess International organizes a HIV/AIDS Treatment Program in Collaboration With the Coca-Cola Africa Foundation and Coca-Cola Bottlers in 56 Countries in Africa: PRNewswire - September 26, 2002; - Program designed to Expand Employee Healthcare Include Prevention, AIDS Testing and Drug Treatment that will start in Southern and Eastern Africa AMSTERDAM, Netherlands , Sept. 26 /PRNewswire/ -- PharmAccess International announced today that it will participate in a program to expand employee healthcare in collabora
Inhibitors of HIV Replication Identified Using Ciphergen Biosystems Technology: PRNewswire - September 26, 2002; - Culmination of 16 Year Hunt Suggests New Therapeutic Strategies in AIDS - FREMONT, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced an important discovery made using their proprietary protein analysis technology: the long-awaited identification of the CD8+ Antiviral
Calypte Biomedical Reports On US Conference on AIDS; Conference Attended by Over 3,500 Healthcare Providers; Pre-IDE Meeting Scheduled October 4th With FDA for Rapid Test: PRNewswire - September 26, 2002; ALAMEDA, Calif. -- Calypte Biomedical Corporation (BULLETIN BOARD: CALY) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, shared information about the benefits and performance of its urine HIV-1 tests at the United States Conference on AIDS (USCA) h
New Software Gives Patients the Tools They Need to Manage Health Conditions Like Diabetes, Asthma, Hypertension and More - Includes First Ever Solution for HIV/Aids Patients: PRNewswire - September 24, 2002; ARLINGTON, Va., Sept. 24 /PRNewswire/ -- FireLogic, Inc. today introduced the next generation of its innovative HealthEngage disease management software. HealthEngage provides an easy to use, yet comprehensive tool for patients to manage their wellbeing from any desktop or handheld computer. Using HealthEngage, patient
Pharmasset, Inc. is a Proud Sponsor of the 2nd Annual Georgia Life Sciences Summit: PRNewswire - September 24, 2002; ATLANTA, Sept. 24 /PRNewswire/ -- Pharmasset, Inc. is pleased to announce its sponsorship of the 2nd annual Georgia Life Sciences Summit -- From Bench to Blockbuster. This event, which is considered the primary gathering of scientists and industry decision makers for Georgia s life sciences community, will take place o
Patent Granted for Preparation of Promising HIV Drug - Chicago-Area Company Advances Calanolide A, Compound Derived From Malaysian Rainforest: PRNewswire - September 24, 2002; WOODRIDGE, Ill., Sept. 24 /PRNewswire/ -- The U.S. Patent and Trademark Office issued a broad patent to Sarawak MediChem Pharmaceuticals of Woodridge, Ill., bolstering the company s proprietary position in the use of calanolides as potential anti-viral drugs, the company announced today. Sarawak MediChem Pharmaceutical
4th Annual AIDS Walk Michigan to be Held on Belle Isle, Sept. 28: PRNewswire - September 23, 2002; DETROIT, Sept. 23 /PRNewswire/ -- The city of Detroit AIDS Walk is a unique collaboration of 25 service organizations in the Detroit area that will host their 4th annual AIDS Walk on Detroit s Belle Isle, Saturday, September 28, 2002. Registration begins at 10 a.m. with the 5K walk scheduled to start at noon come rain
Primagen and Gilead Extend Service Testing Agreement To Use The Retina(TM) Mitox Test For All Samples of Multi-Year Clinical Study: PRNewswire - September 23, 2002; AMSTERDAM, Netherlands , Sept. 23 /PRNewswire/ -- Primagen Holding B.V. announced today that they have extended their service testing agreement with Gilead Sciences , Inc., to measure mitochondrial DNA using the Retina(TM) Mitox test in samples of a multi-year, multi-center phase III clinical study of
Invenux, Inc. Secures Grant From the National Institutes of Health to Initiate A Discovery Program for New Anti-HIV Agents - Second SBIR Phase I Grant for 2002 -: PRNewswire - September 23, 2002; DENVER, Sept. 23 /PRNewswire/ -- Invenux, Inc. announced today that the company was awarded an SBIR grant of $100,000 from the National Institutes of Health to begin a drug-discovery program aimed at producing novel anti-HIV agents. The phase I study will involve the initiation of a program to generate a small molecule
FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B: PRNewswire - September 23, 2002; -- First Nucleotide Analogue for the Treatment of Chronic Hepatitis B : Second Novel Gilead Antiviral Approved in Less than One Year - FOSTER CITY, Calif., Sept. 23 /PRNewswire-FirstCall/-- Gilead Sciences (Nasdaq: GILD) today announced that it received U.S. Food and Drug Administration ( F
At UMDNJ-New Jersey Medical School Innovative Autologous Immune Therapy May Be Answer for Treating AIDS Effectively: PRNewswire - September 23, 2002; - Finding Based on Clinical Trial of New Treatment Developed by BDSI - NEWARK, N.J., Sept. 23 /PRNewswire-FirstCall/ -- A clinical trial by researchers at the University of Medicine and Dentistry of New Jersey (UMDNJ) has shown a new autologous immunotherapy appears to be safe and effective treatment for controlling HI
Basketball Great 'Magic' Johnson, Jr. to Cut Ribbon & Tour San Francisco AIDS Clinic Named in His Honor: PRNewswire - September 20, 2002; -- State-of-the-Art AIDS Healthcare Foundation Facility Offers San Franciscans Improved Access to Quality Care, Services SAN FRANCISCO, Sept. 20 /PRNewswire/ -- AIDS Healthcare Foundation (AHF), the nation s largest provider of specialized HIV/AIDS medical care, is pleased to announce that basketball legend Earvin Mag
Marketing Authorization Application Submitted In European Union For Fuzeon(TM), First HIV Fusion Inhibitor Under Review - EU Filing Submitted Just Days After U.S. Filing --: PRNewswire - September 20, 2002; NUTLEY, N.J. and DURHAM, N.C., Sept. 20 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced the submission of a Marketing Authorization Application to the European Union (EU) for FUZEON(TM) (enfuvirtide), formerly known as T-20, for HIV-1 infection in combination with other antiretroviral
Bid on a Phone Call With the Castaway Voted Off Survivor: Thailand Each Week Or Own a Part of Survivor History: PRNewswire - September 19, 2002; - Survivor Props, Memorabilia, Experience Packages and Castaway Phone Calls To Be Offered on eBay to Benefit the Elizabeth Glaser Pediatric AIDS Foundation SANTA MONICA, Calif., Sept. 19 /PRNewswire/ -- Get ready for a whole new season of Survivor and your chance to own a piece of television history. Ever wondered what
Mymetics Announces Appointment of Senior Management Team and Formation of Its Scientific Advisory Board: PRNewswire - September 19, 2002; ANNAPOLIS, Md., Sept. 19 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX), an international biotechnology firm focused on molecular mimicry and retroviral diseases, announced today the appointment of its senior management team and scientific advisory board. The senior management includes Peter
Calypte's Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States - West Virginia Department of Insurance Amends Rule to Include Urine HIV-1 Antibody Testing: PRNewswire - September 19, 2002; ALAMEDA, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that the West Virginia Office of the Insurance Commissioner has cleared the way f
VaxGen to Present at UBS Warburg Life Sciences Conference on Oct. 8: PRNewswire - September 18, 2002; BRISBANE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- VaxGen , Inc. (Nasdaq: VXGN) is scheduled to present at the UBS Warburg Global Life Sciences Conference at 4 p.m. Eastern time, Oct. 8, 2002 at the Plaza Hotel in New York. Lance K. Gordon, Ph.D., VaxGen s CEO, will represent VaxGen at the conference. Dr. Gordon
Governor Gray Davis Signs Bill AB 2197: - Landmark California AIDS Care Bill Extends Medi-Cal Coverage To HIV Positive, Non-Disabled: PRNewswire - September 18, 2002; - Action on Assemblyman Paul Koretz s (D, West Hollywood) Bill Received Overwhelming Editorial Support From State s Top Newspapers, Called Most Important AIDS Policy Bill Nationwide This Year, By AIDS Healthcare Foundation President Michael Weinstein LOS ANGELES, Sept. 18 /PRNewswire/ -- Honoring a campaign pledge made
Ushercell Leads Microbicide Research with CONRAD - Additional Funding Will Accelerate Results: PRNewswire - September 18, 2002; TORONTO, Sept. 18 /PRNewswire-FirstCall/ -- Polydex Pharmaceuticals Ltd. (Nasdaq: POLXF) announces continued progress in the development of Ushercell, the patented lead development product for Polydex. Ushercell has completed three Phase I/II clinical trials and further Phase I/II clinical trials are ongoing. Ushercell
Triangle Pharmaceuticals Announces Final Settlement Of Patent Disputes Involving Amdoxovir (DAPD): PRNewswire - September 17, 2002; DURHAM, N.C., Sept. 17, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today announced the final settlement of patent disputes involving Triangle s drug candidate amdoxovir. Amdoxovir is a purine nucleoside analogue for the treatment of HIV disease. Triangle licensed amdoxovir from Emory U
California Representatives Cross Party Lines to Back Increase for AIDS Drugs: PRNewswire - September 17, 2002; - AIDS Healthcare Foundation Praises Thirty California Representatives Joining Mary Bono, Henry Waxman, Doug Ose, and Diane Watson in Effort to Boost AIDS Drug Assistance Program (ADAP) LOS ANGELES, Sept. 17 /PRNewswire/ -- Thirty of California s representatives in Congress today joined across party lines to ask House
Detroit Artists Unite in the Fight Against AIDS at the Eighth Annual 'ART WORKS FOR LIFE' on September 28: PRNewswire - September 17, 2002; FERNDALE, Mich., Sept. 17 /PRNewswire/ -- Over 200 of Detroit s most prominent artists will donate original pieces of art to be auctioned at the eighth annual ART WORKS FOR LIFE. This exciting event will begin at 6:30 p.m. on Saturday, September 28, 2002 at the Edsel and Eleanor Ford House in Grosse Pointe Shores to be
DaimlerChrysler Recognized for HIV/AIDS Initiative: PRNewswire - September 17, 2002; WASHINGTON, Sept. 17 /PRNewswire-FirstCall/ -- The Constituency for Africa (CFA) recently presented DaimlerChrysler AG with its Corporate Leadership Award in recognition of the company s commitment to combating the HIV/AIDS Pandemic in Africa. The award was presented at the organization s annual awards ceremony last we
Clothes Minded Teens Open Hearts for AIDS - Tech Pairs With Fashion as Microsoft and Macy's Team Up for Passport 20/02 - Wednesday, September 18, 2002: PRNewswire - September 17, 2002; WHO: Teens will test their tech and fashion flair at Microsoft s Outsmart Encarta and Strike a Pose stages at Macy s Passport 20/02. Teens will model their quest for knowledge by offering smart answers to shock jock Strawberry from WILD 94.9, who will ask some tough trivia questions at the Outsmart Encarta stage.
Bayer Receives FDA Approval for VERSANT(R) HIV bDNA Viral Load System - Assay Generates More Confident Results for Physicians and Patients -: PRNewswire - September 17, 2002; TARRYTOWN, N.Y., Sept. 17 /PRNewswire/ -- Bayer Diagnostics announced today that it received US Food and Drug Administration approval for VERSANT(R) HIV-1 RNA 3.0 Assay (bDNA)*, its nucleic acid probe diagnostic assay for the direct quantification of HIV-1 RNA in the plasma of people living with HIV. VERSANT(R) HIV bDN
Roche and Trimeris Submit New Drug Application for FUZEON(TM), First Fusion Inhibitor to be Reviewed by FDA: PRNewswire - September 17, 2002; NUTLEY, N.J. and DURHAM, N.C., Sept. 17 /PRNewswire-FirstCall/ -- Roche and Trimeris, Inc. (Nasdaq: TRMS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for approval to market FUZEON(TM) (enfuvirtide), formerly known as T-20. FUZEON is the frontrunner in
United States Conference on AIDS this Week in Anaheim, CA - Nation's Largest Gathering of HIV/AIDS Community: PRNewswire - September 16, 2002; WASHINGTON, Sept. 16 /PRNewswire/ -- An unintended casualty of last year s horrific events of September 11 was the cancellation of the 2001 United States Conference on AIDS scheduled to begin just two days later in Miami Beach. For the first time since that fateful day, HIV/AIDS treatment leaders, advocates and front-l
Delmar Learning Releases Latest Editions of OSHA and OBRA Handbooks to Help Health Care Facilities Satisfy Government Standards: PRNewswire - September 16, 2002; ALBANY, N.Y., Sept. 16 /PRNewswire/ -- Delmar Learning, a leader in educational resources for lifelong learning and part of The Thomson Corporation (NYSE: TOC; TSX: TOC), today announced the release of the latest editions of health care facilities handbooks covering OSHA and OBRA guidelines. The third edition of The OS
New PhRMA Survey Finds 249 Medicines in the Pipeline for African Americans: PRNewswire - September 13, 2002; WASHINGTON, Sept. 13 /PRNewswire/ -- Pharmaceutical and biotechnology companies are working on 249 new medicines for diseases that disproportionately afflict African Americans or diseases that are among the top 10 causes of death among African Americans, according to a new survey by the Pharmaceutical Research and Manu
Media Advisory: Dame Elizabeth Taylor Appears One Night Only At Macy's Passport '02 20th Anniversary Gala On Thursday, September 19th in San Francisco - Earvin 'Magic' Johnson Hosts the American Express Cardmember Evening on Friday, September 20th: PRNewswire - September 13, 2002; WHO: DAME ELIZABETH TAYLOR hosts Macy s Passport 20/02 s Gala Evening on September 19, America s premier HIV/AIDS fundraiser and fashion show featuring the best of Macy s fall collections for men, women and children. Presented by American Express, this year the show includes a special performance by classical violinist
Calypte Biomedical to Attend US Conference on AIDS: PRNewswire - September 12, 2002; ALAMEDA, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, said the company will attend the United States Conference on AIDS (USCA) in Anaheim, CA, Sept
Micrologix Expands Pipeline through Acquisition of Antiviral Product & Technology Portfolio - Antiviral Technologies focused on Human Papillomavirus (HPV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV): PRNewswire - September 12, 2002; VANCOUVER, Sept. 12 /PRNewswire-FirstCall/ - Micrologix Biotech Inc. (TSX: MBI; US OTC: MGIXF) has acquired a broad portfolio of antiviral technologies and product candidates (the Portfolio ) formerly owned and/or being developed by Origenix Technologies Inc. (the Origenix Intellectual Property ). These technologies an
BioDelivery Sciences International, Inc. Receives NIH Grant to Develop An Oral Prophylactic/Therapeutic HIV Vaccine in Collaboration With Biokeys Pharmaceuticals, Inc.: PRNewswire - September 12, 2002; NEWARK, N.J., Sept. 12 /PRNewswire-FirstCall/ -- BioDelivery Sciences International (Nasdaq: BDSI; BDSIW) announced today that they have received a two year $600,000 National Institutes of Health (NIH) SBIR Grant to develop an oral form of a powerful HIV prophylactic/therapeutic vaccine with their patented Bioral(TM) d
Real People. Real Stories. AIDS Walk Detroit: HIV Positive Man Walks to Reinforce His Passion for Life: PRNewswire - September 10, 2002; ROYAL OAK, Mich., Sept. 10 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk. They include, Bill, an HIV positive
Euroscreen Awarded US Patent Covering Key HIV Target - CCR5 Chemokine Receptor is a Crucial Target for a Novel Aids Therapy -: PRNewswire - September 10, 2002; BRUSSELS, Belgium , Sept 10 /PRNewswire/ -- Euroscreen s.a., a world leader in G-protein-coupled receptors (GPCRs), today announced the issue of a key US patent in the area of HIV infection. The patent claims a specific GPCR sequence included in the human CCR5 receptor. The CCR5 receptor has a central role in the mecha
The Immune Response Corporation Announces Restructuring and Cost Reductions To Focus Exclusively On REMUNE(R) - Ronald B. Moss M.D. Is Named President: PRNewswire - September 9, 2002; CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Signaling a move to restructure and reposition the Company for potential product commercialization, The Immune Response Corporation (Nasdaq: IMNR) announced today a restructuring program and management changes aimed at reducing costs and refocusing the Company on its
Expanding Multi-Resistant HIV Populationin Need of New Classes of Drugs - Trimeris' T-20 HIV Drug Poised to Address Key Unmet Need in These Patients, According to a New Report from Decision Resources: PRNewswire - September 9, 2002; WALTHAM, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, Inc., one of the world s leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that the expanding multi-resistant HIV population is in need of new classes of drugs. One such drug that could prove valuable to the
US' Largest AIDS Organization Calls Glaxo AIDS Drug Announcement a 'Hollow Gesture': New Price Remains Seven Times Higher Than Generics: PRNewswire - September 6, 2002; - AIDS Healthcare Foundation Says Tragic Glaxo Decision Won t Save Lives, Denounces Cynical P.R. Effort Against Lawsuit LOS ANGELES, Sept. 6 /PRNewswire/ -- The United States largest AIDS organization described yesterday s AIDS drug price reduction announcement by British-owned GlaxoSmithKline a hollow gesture th
Real People. Real Stories. AIDS Walk Detroit; Ferndale Woman Walks to Honor the Memory of Her Father: PRNewswire - September 6, 2002; ROYAL OAK, Mich., Sept. 6 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk. They include, Yvette, whose father, J
National HIV/AIDS Conference Takes Place in Atlanta, Oct. 11-12: Conference to Unveil Research Results and Focus on Advances and Treatment Options for HIV patients: PRNewswire - September 6, 2002; ATLANTA, Sept. 6 /PRNewswire/ -- Results from the scientific study, HEDS UP (HIV Early Detection Study of Unrecognized Positives), will be unveiled at a national HIV/AIDS Conference on Friday, Oct. 11 and Saturday, Oct. 12 at the Swissotel in Buckhead. The HEDS UP study found that 40 percent of patients diagnosed with
Gen-Probe Announces Results From the Initial Field Evaluation of The TIGRIS(TM) Instrument System for Clinical Diagnostic Testing: PRNewswire - September 5, 2002; SAN DIEGO, Sept. 5 /PRNewswire/ -- Gen-Probe Incorporated, an established leader in molecular diagnostics based on its patented nucleic acid testing ( NAT ) technologies, today announced results from the initial field evaluation (beta trial) of the Company s TIGRIS System for clinical diagnostic testing. Two applicatio
HIV Medication Adherence Worsens Following September 11 Attacks: PRNewswire - September 5, 2002; -Patients taking medications for HIV were more likely to miss doses or take doses later following the events of 9/11, according to a study from the Center for HIV Educational Research and Training (CHEST) published on GayHealth.com NEW YORK, Sept. 5 /PRNewswire/ -- Gay and bisexual men with HIV on HAART (Highly Active
Triangle Pharmaceuticals, Inc. Submits New Drug Application for Coviracil(R) For the Treatment of HIV Disease: PRNewswire - September 4, 2002; DURHAM, N.C., Sept. 4, 2002 /PRNewswire-FirstCall/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for marketing approval of Coviracil for the treatment of HIV disease. Coviracil is a potent, once-a-day Nucleoside Rever
HIV Pioneer Encourages Chinese Health Authorities to Take 'Full Advantage' Of Calypte's HIV-1 Urine Screening Test: PRNewswire - September 3, 2002; ALAMEDA, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, announced today that HIV pioneer Professor Luc Montagnier, co-discoverer of HIV-1 and discoverer o
Hemispherx Biopharma Will Be Presenting at The Wall Street Analyst Forum in New York on September 9, 2002: PRNewswire - September 3, 2002; PHILADELPHIA, Sept. 3 /PRNewswire-FirstCall/ -- Hemispherx Biopharma, Inc. (Amex: HEB), a biopharmaceutical company focused in the experimental-stage development of immune-based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, today announced that Dr. William Carter, Chairman and CE
Innovative Australian HIV Drug Gets Green Light for Further Testing: PRNewswire - September 3, 2002; MELBOURNE, Australia , Sept. 3 /PRNewswire-FirstCall/ -- * Milestone in Australian HIV drug development with new study piggy-backing on current VIR201 treatment trial * Now testing VIR201 as independent therapy without accompanying anti-retroviral medications * New medication may provide relief from rigid routine and p
MTV, Kaiser Family Foundation Win Emmy for 'Be Safe/Fight for Your Rights: Protect Yourself' Campaign: PRNewswire - August 30, 2002; NEW YORK, Aug. 30 /PRNewswire/ -- Last night, MTV: Music Television and the Kaiser Family Foundation accepted a National Emmy Award for Be Safe/Fight for Your Rights: Protect Yourself, a national public education campaign that informs young people about sexual health issues such as HIV/AIDS and STDs via public service
Transplants in HIV Patients Should Proceed, But Drug Interactions Can Be Concern, Concludes Research at International Congress of The Transplantation Society: PRNewswire - August 29, 2002; MIAMI, Aug. 29 /PRNewswire/ -- While historically surgeons have been reluctant to transplant patients with the human immunodeficiency virus (HIV), in recent years, some centers have begun to accept patients with well- controlled HIV as candidates for liver or kidney transplantation. Based on results of three studies fr
The National Academy of Television Arts & Sciences Presents Its 2001 Community Service and PSA Emmy Awards: PRNewswire - August 29, 2002; NEW YORK, Aug. 29 /PRNewswire/ -- Reality TV used to evoke open and honest discussions about race, a campaign that tells the importance adults play in a child s education and an awareness program about HIV and sexual health issues were honored last night as the National Academy of Television Arts & Sciences present
New Approaches Promote Shared Responsibility for Women and Men to Prevent HIV And Unplanned Pregnancy: PRNewswire - August 28, 2002; -Grants Totaling $48 Million to Fund Research and Development of New Approaches To Contraception and Disease Prevention SEATTLE, Aug. 28 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced a series of grants that will combine innovative uses of existing tools with research and development of technol
Governor Signs AB 2064 (Cedillo, D, Los Angeles) - Bill Paves Way for New Approach to HIV Testing: PRNewswire - August 28, 2002; -Law Enables Community-based, Nonprofit Organizations With Demonstrated Expertise to Conduct Counselor Training for State s HIV Testing Programs -AIDS Healthcare Foundation Gears Up to Target Hard-to-Reach Populations in Sex Clubs, Bath Houses and Via Mobile Testing Van -Preliminary July 2002 Alternative Testing Site R
Real People. Real Stories. AIDS Walk Detroit - Allen Park man lost his close friend to AIDS after 5 year battle: PRNewswire - August 28, 2002; ROYAL OAK, Mich., Aug. 28 /PRNewswire/ -- AIDS Walk Detroit has hit the streets with its 2002 campaign, Real People. Real Stories. As part of this campaign, 5 area residents whose lives have been touched by HIV and AIDS are telling their stories in support of the September 15 Walk to be held in Downtown Royal Oak. They
Panacos Pharmaceuticals Awarded $143,000 Grant to Discover Novel Drugs for Respiratory Syncytial Virus Infection: PRNewswire - August 28, 2002; Company Extends Its Fusion Inhibitor Technology to New Viral Target GAITHERSBURG, Md., Aug. 28 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has been awarded a Phase I Small Business Innovative Research (SBIR) Grant of $143,000 by the National Institutes of Health (NIH). The award will help supp
Calypte to Accelerate Development of Rapid HIV Urine Test: Schedules Pre-IDE Meeting With FDA for Early October: PRNewswire - August 27, 2002; ALAMEDA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY) the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced that based upon positive preliminary results which have yielded 100 percent specifi
New AIDS Therapy Research to Be Presented at ICAAC in September: PRNewswire - August 27, 2002; ANNAPOLIS, Md., Aug. 27 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX) today announced that the first major poster presentation of the Company s new approach to treating HIV and other retroviral diseases will take place next month at the Interscience Conference on Antimicrobial Agents and Che
bd's mongolian BBQ Celebrates 10 Years; Restaurant Honors Association with AIDS Walk Detroit: PRNewswire - August 26, 2002; ROYAL OAK, Mich., Aug. 26 /PRNewswire/ -- Royal Oak based bd s mongolian barbeque, a chain of restaurants with 28 locations spread across 12 states, celebrated its 10 year anniversary on Thursday, August 22, 2002 with an invitation only party at its Royal Oak establishment. At the event, Billy Downs, owner and founder
Steven Spielberg to Accept HRC National Equality Award: Singer Melissa Etheridge to Present Award at Sixth Annual HRC National Dinner: PRNewswire - August 26, 2002; - Talk Show Host Cristina Saralegui, the Latin Oprah, to Accept HRC Civil Rights Award - Rep. Richard Gephardt, D-Mo., is Featured Speaker WASHINGTON, Aug. 26 /PRNewswire/ -- The Human Rights Campaign proudly announced today that filmmaker Steven Spielberg will accept the 2002 Human Rights Campaign National Equality Aw
Revolutionary Medication Compliance Technology, The Pill Timer(TM), Gives New Hope for People With HIV: PRNewswire - August 23, 2002; MED TIME TECHNOLOGY INTRODUCES THE PILL TIMER Med Time Technology, Inc. s new invention, The Pill Timer, is the only medication monitoring and compliance device that s recommended by pharmacists and meets USP safety standards. This helps individuals who sometimes forget to take their medications. Medicine must be taken
Evotec OAI Grants Licence to Roche Diagnostics: PRNewswire - August 22, 2002; HAMBURG, Germany and ABINGDON, England, Aug. 22 /PRNewswire-FirstCall/ -- Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced that it granted a licence to Roche Diagnostics GmbH, the German affil
Roche Molecular Systems Initiates U.S. Clinical Trials Of COBAS AmpliScreen(TM) HBV Test Researchers: Study to Shed New Light on Highly Infectious, Often 'Silent,' Transfusion-Transmitted Virus, Hepatitis B: PRNewswire - August 22, 2002; PLEASANTON, Calif., Aug. 22 /PRNewswire/ -- Roche Molecular Systems, Inc. (Roche) today announced the start of comprehensive clinical trials of its COBAS AmpliScreen(TM) HBV Test. The trials mark an important milestone because, for the first time in the U.S., Roche s PCR nucleic acid amplification technology (NAT) test
Chiron Appoints Jack Goldstein President, Chiron Blood Testing : New Business Unit Head Brings Substantial Operating Experience to Blood Testing Division: PRNewswire - August 22, 2002; EMERYVILLE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR) today named Jack Goldstein, 55, as president of Chiron s Blood Testing division. Based in Emeryville, Dr. Goldstein will be responsible for the commercial operations of Chiron s blood testing business. He will also serve as a member
Trinity Medical Group USA Announces REMUNE(R) Study Results In Slowing HIV Progression and Overcoming Specific Drug Resistance In Antiretroviral Therapies Two Studies Were Presented at FASEB Conference on Therapeutic and Preventive HIV Vaccines: PRNewswire - August 22, 2002; RANCHO SANTA MARGARITA, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Trinity Medical Group USA, Inc. (OTC Bulletin Board: TMGU) today publicly announced clinical results presented at a scientific conference on therapeutic and preventive HIV vaccines indicating that HIV-positive patients in Thailand taking highly ac
Alonzo Mourning Launches National Campaign to Help Chronically Ill Patients With Anemia: Exhaustion Most Frequent and Significant Symptom Related to Serious Chronic Diseases, According to Harris Interactive Survey: PRNewswire - August 20, 2002; ORTHO BIOTECH TO DISTRIBUTE REBOUND FROM ANEMIA BROCHURE: Pro basketball star Alonzo Mourning and Ortho Biotech Products, L.P. are distributing a free brochure, Rebound from Anemia, to educate and encourage the millions at risk for anemia. For more information about the program, call 1-800-251-0627 or visit www.procrit
ADVR's Product R Subject of Published Study on Clinical Trial For Treatment of HIV/AIDS: Study Concludes Product R Patients Had Increased CD-4 Cell Counts and Weight Gains Compared to Placebo Patients: PRNewswire - August 20, 2002; YONKERS, N.Y., Aug. 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that the results of a randomized, controlled and blinded clinical study of Product R therapy in patients with HIV/AIDS have been published in the July/August 2002 issue of HIV Clinical Trials. This
Students Rally for AIDS Walk Detroit; Grosse Pointe North High School Builds a Team for September 15 Walk: PRNewswire - August 19, 2002; ROYAL OAK, Mich., Aug. 19 /PRNewswire/ -- On Sunday, August 11, 2002, Danielle Dipert, Dan Gilleran and Sara Johnson, team leaders for the Grosse Pointe North High School Walk Team, and approximately 40 other students and teachers gathered for a kick-off rally to begin building their team for AIDS Walk Detroit 2002. Th
FDA Approves Kytril For The Prevention and Treatment of Post-Operative Nausea and Vomiting - Studies Show Kytril Significantly More Effective Than Placebo: PRNewswire - August 19, 2002; NUTLEY, N.J., Aug. 19 /PRNewswire/ -- Roche announced today that the U.S. Food and Drug Administration ( FDA ) granted approval of its antiemetic, Kytril(R) Injection (granisetron hydrochloride) for both the prevention and treatment of post-operative nausea and vomiting (PONV). When used for prevention, Kytril is given
Virax to Develop Hepatitis B Treatment With New York Blood Center: PRNewswire - August 19, 2002; MELBOURNE, Australia , Aug. 19 /PRNewswire-FirstCall/ -- * Virax expands development program into third product area * Prestigious US organisation seeks Virax collaboration * Visit http://www.virax.com.au for more information Virax Holdings Limited (ASX: VHL) announced today that it has signed a development agreement w
Hemispherx Biopharma Receives Letter of Intent for Potential Multimillion-dollar Investment by Royal Family of United Arab Emirates - Understanding Announced at Annual Meeting in Philadelphia: PRNewswire - August 19, 2002; -- Global Technology Expands as Company-held Patents Approach the 400 Mark -- Clinical Trial for HIV and Hepatitis C Set to Start in Spain PHILADELPHIA, Aug. 19 /PRNewswire-FirstCall/ -- Hemispherx Biopharma has received a Letter of Intent for a potential multimillion-dollar investment in the Company by the Royal Famil
First 2003 Nissan 350Z(TM) - VIN #0000001 - to be Available on eBay Motors; All Proceeds Will Benefit the Elizabeth Glaser Pediatric AIDS Foundation: PRNewswire - August 19, 2002; GARDENA, Calif., Aug. 19 /PRNewswire/ -- Nissan North America, Inc., (NNA) today announced that the first 2003 Nissan 350Z(TM), VIN 0000001, will be available for bidding on eBay Motors. Nissan, in conjunction with the Entertainment Industry Foundation, will donate the winning bid amount to the Elizabeth Glaser Pediatr
Roche and Trimeris Open Physician Enrollment For Fuzeon(TM) U.S. Early Access Program: PRNewswire - August 16, 2002; NUTLEY, N.J. and DURHAM, N.C., Aug. 16 /PRNewswire/ -- Responding to patient need, Roche and Trimeris today announced that physician enrollment for the U.S. Early Access Program for Fuzeon(TM)* (enfuvirtide), formerly known as T-20, will open on Monday, August 19. This program, running parallel with other controlled Fu
The Immune Response Corporation Announces Results From Trial of REMUNE(R) In Treatment Interruptions for Chronic HIV Infection - Results Indicate Approach Allowed for Extended Periods Off Antiretroviral Therapy: PRNewswire - August 15, 2002; CARLSBAD, Calif., Aug. 15 /PRNewswire-FirstCall/ -- Indicating for the first time in a clinical trial that REMUNE(R) might give relief for HIV- infected patients from the adverse side-effects of antiretroviral therapies, The Immune Response Corporation (Nasdaq: IMNR) announced today results from an ongoing study by the
Calypte Files 10-Q and Submits Financial Certification With the SEC: PRNewswire - August 14, 2002; ALAMEDA, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CALY) today announced that its Chairman Anthony Cataldo, CEO Nancy Katz, and CFO Richard Brounstein today affirmed the accuracy of Calypte s Form 10-Q for the period ending June 30, 2002 as filed with the Securities a
Gen-Probe Reports Second Quarter 2002 Financial Results - Company recognizes initial commercial revenues in the United States from its HIV-1/HCV blood screening assay: PRNewswire - August 14, 2002; -- Gen-Probe distribution to the shareholders of Chugai expected on or about September 15, 2002; Company expects to begin trading on the Nasdaq National Market(R) under ticker symbol GPRO on September 16, 2002 SAN DIEGO, Aug. 14 /PRNewswire/ -- Gen-Probe Incorporated, an established leader in molecular diagnostics base
Norzyme(TM) Awarded Grant by National Institutes of Health - Million Dollar Grant to Fund Clinical Trials on HIV-AIDS Patients: PRNewswire - August 14, 2002; CHICAGO, Aug. 14 /PRNewswire/ -- Norzyme, Inc., developers of in-vitro diagnostic technology for therapeutic drug monitoring, today announced the National Institutes of Health (NIH) has further recognized the promise of its Levoprin-ZG(TM) product to aid in the disease management of HIV-AIDS patients with the award of
Epimmune Issued Additional Patent for PADRE(R) Technology - Patent Includes Claims Covering Compositions and Methods For Inducing Immune Responses in Humans: PRNewswire - August 13, 2002; SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced that the U.S. Patent and Trademark Office recently issued the Company a patent
Data From Cohort Study Showed Better Virologic Response in Regimens Containing SUSTIVA(R) Compared to Viramune(R)-Containing Regimens in HIV Treatment-Naive Patients: PRNewswire - August 12, 2002; PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Data from a large observational cohort study published in the July/August issue of HIV Clinical Trials showed that anti-HIV combination treatment regimens containing SUSTIVA(R) ( efavirenz ) had a better virologic response than regimens containing
Group Led by Johns Hopkins Center for Communication Programs Wins $127 Million for Global Health Communication Project - Award Will Fund Programs to Combat Public Health Threats Such as HIV/AIDS: PRNewswire - August 9, 2002; BALTIMORE, Aug. 9 /PRNewswire/ -- A group led by the Johns Hopkins University Center for Communication Programs (JHU/CCP) has been awarded $127 million by the U.S. government to implement a five-year global project designed to use strategic communication to fight infectious diseases such as HIV/AIDS, TB, and malaria; i
Flashback: CAGW AIDS Report Uncovers Federal Programs Abuse; New White House and CDC Inquiries Bolster February Report: PRNewswire - August 8, 2002; WASHINGTON, Aug. 8 /PRNewswire/ -- In response to new government inquiries into abuse and mismanagement in federal AIDS programs, Citizens Against Government Waste, the nation s largest taxpayer watchdog, today re-released its February 2002 report, AIDS Programs: An Epidemic of Waste. (See the report at http://www.cagw
Epimmune Reports Second Quarter 2002 Financial Results: PRNewswire - August 8, 2002; SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Epimmune Inc. (Nasdaq: EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body s immune system, today announced its financial results for the second quarter ended June 30, 2002. Second quarter
Los Angeles Latino Community, Corporate and Medical Leaders Gather For HIV/AIDS Benefit at House of Blues: PRNewswire - August 8, 2002; WHAT: Una Noche de Esperanza (A Night of Hope), seventh-annual awards dinner and art auction to benefit AltaMed Health Service, a leading organization focusing on growing HIV/AIDS crisis in the Latino community. The concert-style event will also include celebrity appearances and entertainment. WHEN: Sunday, Aug
ViroLogic Announces Data on Increase in HIV Drug Resistance Published In New England Journal of Medicine - Results Strongly Supports Resistance Testing for Newly-Infected Individuals: PRNewswire - August 8, 2002; SOUTH SAN FRANCISCO, Calif., Aug. 8 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC